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ABSTRACTS OF MEMBERS' PROFFERED PAPERS
CHLOROACETALDEHYDE, A VINYL
CHLORIDE METABOLITE, INDUCES
ERRORS DURING IN VITRO DNA
SYNTHESIS. J. A. HALL & R. SAFFHILL,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester
Chloroacetaldehyde (CA), a rearranged meta-
bolic product of the human carcinogen vinyl
chloride, has been shown to be mutagenic in
certain microbial systems as well as towards
mammalian cells. CA has been reacted with
the alternating DNA-like polymers poly(dA-
dT) and poly(dC-dG) when, as with DNA,
etheno-adducts of the adenine and cytosine
bases are formed. These treated polymers,
when used as templates for E. coli DNA
polymerase I, show a decreased ability to
direct DNA synthesis. This is accompanied
by an increase in the relative levels of non-
complementary nucleotides incorporated into
the newly synthesised DNA-like material.
This increased with the amount of modified
base present in the templates used. With the
poly(dA-dT) templates one dGMP residue
was incorporated for every 60 +etheno-
adenine residues present, whilst no dCMP
misincorporation was detected. One mis-
incorporation of dAMP or dTMP occurred in
the presence of 30 + and 80 + ethenocytosine
residues respectively in the poly(dC-dG)
templates. For the modified poly(dC-dG)
templates, a nearest-neighbour analysis shows
that the majority of the errors were incor-
porated opposite the cytosine (or modified
cytosine) bases. Extensive analyses of the
modifications present in the templates indi-
cate that the misincorporations observed are
not due to the presence of apurinic sites or to
the formation of uracil or xanthine by de-
amination of the cytosine or adenine bases
respectively. We conclude that the non-
complementary nucleotide incorporations
probably arise from the presence of etheno-
adducts in the templates used.
ALKYLATION, PERSISTENCE OF
DNA LESIONS, CELL SURVIVAL AND
MUTATION IN 4 RODENT TUMOUR
CELL LINES AFTER EXPOSURE TO
N - METHYL - N - NITROSOUREA
(MNU). L. DURRANT, G. P. MARGISON &
J. M. BOYLE, Paterson Laboratories, Christie
HospitalandHoltRadiumInstitute, Manchester
Dose response curves for colony forming
ability were determined following incubation
with MNU for 30 min at 37°C. The Do values
were 0 7, 0 3, 0 4 and 0 07 mm MNU for
Chinese hamster cell lines V79 and V79/79,
rat Yoshida sarcoma (YS), and mouse leu-
kaemia L1210 cells respectively. Induced
mutation frequencies for resistance to 6-
thioguanine were 13-8, 16-3 and 17-0x10-4
per mm MNU for V79, V79/79 and L1210
respectively. The methylated purines 06-
methylguanine (06-meG), N7-methylguanine
(N7-meG) and 3-methyladenine (3-meA) were
determined onDNAhydrolysates extracted at
various times after MNU exposure. There was
good correlation between cell survival and
total methylated purines for all cell lines
except L1210, which showed excessive killing.
The half-lives of N7-meG and 3-meA varied
among the cell lines, from 15-30 h and 3-6-
7-2 h respectively. The half-life of 06-meG
was >100 h, 21 h, 5.7 h and 49-5 h in V79,
V79/79, YS and L1210 respectively. Cell-free
extracts ofYS and L1210 were tested for their
ability to destroy 06-meG when incubated
with methylated DNA in vitro. The activity
from YS was at least twice that from L1210.
These results indicate that cell survival
is not always related to the level of DNA
alkylation, and induced mutation frequency
does not correlate with the rate of 06-meG
removal in these cell lines.
PRETREATMENT OF RATS WITH A
SINGLE DOSE OF ACETYLAMINO-
FLUORENE INCREASES THE CAPA-
CITY OF LIVER ENZYMES TO
MOVE O6-METHYLGUANINE FROM
DNA IN VIVO AND IN VITRO. D. P.
COOPER, G. P. MARGISON & P. J. O'CONNOR,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester
Chronic pretreatment of rats with AAF has
been shown to enhance the repair of 06-
methylguanine (06-meG) (Buckley et al.,
1979; Nature 281) and similar effects have
now been obtained using single-dose pre-
treatments. Male Wistar rats were given
AAF up to 20 mg/kg; i.p. 24 h before a single
dose (1 mg/kg, i.p.) of [14C]-dimethylnitro-
samine (DMN). 5 h after the DMN challenge
there were some variations in the amounts
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of 7-methylguanine (7-meG) and 3-methly-
adenine (3-meA) in the liver DNA of control
and pretreated groups. However, the 3-
meA/7-meG ratio was similar in all cases,
whilst the 06-/7-meG ratio was reduced
after 20 mg AAF/kg, suggesting that repair
of 06-meG was enhanced. The effect was not
specific for DMN-induced damage, as the
repair of 06-meG produced in liver by MNU
was also enhanced. Incubation of cell-free
liver extracts with MNU-methylated DNA
in vitro decreased the amount of 06-meG in
the acid precipitable DNA. This decrease was
protein-dependent, but no free 06-meG base
was found in the acid supernatants. Extracts
from control rats destroyed 21% of the 06-
meG in the substrate, whilst extracts from
animals pretreated with 6-67, 20 or 60 mg
AAF/kg destroyed 40, 77 and 90% of the
06-meG respectively. The effects observed in
vivo were therefore probably due to an
increased production of repair enzyme. AAF
pretreatment did not affect 7-meG glyco-
sylase activity in cell-free extracts. There
was a 20-fold increase in the incorporation of
[3H]-dT into hepatic DNA of rats pretreated
with 20 mg AAF/kg, whilst lower doses had
no effect. The enhancement of 06-meG repair
could therefore be related either to cell pro-
liferation as a result of the hepatotoxicity of
AAF or to the induction ofrepair enzymes in
response to sublethal DNA damage.
EFFECT OF CHRONIC DIALKYNI-
TROSAMINE ADMINISTRATION ON
ALKYLGUANINE REMOVAL FROM
SYRIAN GOLDEN HAMSTER LIVER
DNA. R. A. SMITH & G. P. MARGISON,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester
Chronic administration of low doses of
dimethylnitrosamine (DMN) or diethylnitro-
samine (DEN) specifically enhances the
enzymic removal of the promutagenic base,
06-alkylguanine from rat liver DNA (Monte-
sano et al., 1979, Cancer Res., 39; Margison
et al., 1979, Br. J. Cancer, 40). Investigations
in Syrian golden hamsters indicate that the
efficiency of 06-alkylguanine removal from
liver DNA is decreased after similar dose
schedules. Once-weekly administration of
unlabelled DMN (3 mg/kg s.c.) led to an
increase in the amount of 06-methylguanine
(meG) produced by a single s.c. dose of 3 mg/
kg [14C]-DMN in comparison with controls.
The kinetics of meG removal after adminis-
tration of DMN (2 mg/kg/day i.p. on week-
days for 3 weeks) showed the increased
amounts of 06-meG in DNA were due to an
inhibition or overloading of the enzyme in-
volved. Daily DMN administration consider-
ably increased the incorporation of 1-carbon
fragments from [14C]-DMN into DNA purines
indicating that the schedule had increased
DNA turnover without enhancing 06-meG
removal. Administration of DEN (10 mg/kg/
day i.p. on weekdays for 3 weeks) also pro-
duced increased amounts of 06-ethylguanine
in DNA compared to controls given a single
dose of 10 mg/kg-[14C]-DEN, indicating
that the 06-meG removal system acts on or is
similarly affected by pretreatment with
ethylating agents. The overloading of 06
alkylguanine removal during chronic ad-
ministration of dialkylnitrosamines may be a
significant factor in the induction of liver
tumours in Syrian hamsters.
EFFECT OF AFLATOXIN B1 ON THE
REPAIR OF O6-METHYLGUANINE IN
THE HEPATIC DNA OF RATS AND
MICE. G. B. MARU, G. P. MARGISON, Y-H.
CHU & P. J. O'CONNOR, Paterson Laboratories,
Christie Hospital and Holt Radium Institute,
Manchester
Pretreatment of male Wistar rats by i.p.
injection of single (2 mg/kg) or multiple (4 x
0-5 mg/kg) doses of aflatoxin B1 (AFB)
stimulates the process for the removal of
06-methylguanine from hepatic DNA in
animals challenged with a single dose
(2 mg/kg) of [14C]-dimethylnitrosamine
(DMN). The sensitivity of this system, in
terms of its ability to "adapt", is indicated
by the fact that the repair response can be
detectedasearly as onedayafterpretreatment
with a single dose (Chu et al., 1981, Br.
J. Cancer, 43, 850). However, treatment of
mice (C57BL, males) with doses from 0-1 to
100 mg/kg of AFB, had no marked effect on
the activity of the 06-meG repair system,
when assayed in vitro using cell-free liver
extracts and DNA methylated with [3H]-
MNU as substrate. This murine repair system
has been titrated in vivo, using a range of
doses of[14C]-DMN (0-25-10 mg/kg). In terms
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of saturation kinetics it appears to be inter-
mediate between the Syrian golden hamster
(Stumpf et al., 1979, Cancer Res., 39, 50), and
the rat (Pegg & Hui, 1978, Biochem. J., 173,
739). but more closely resembling that for
the rat. Different doses of AFB and exposure
periods are under investigation, but it is
tentatively concluded that the mouse, like
the hamster and in contrast to the rat, is
refractory to the inducibility of the 06-meG
repair system.
DISTRIBUTION OF BENZO(A)-
PYRENE-DNA ADDUCTS WITHIN
MAMMALIAN CHROMATIN. P. L. JACK
& P. BROOKES, Chemical Carcinogenesis
Division, Institute ofCancer Research, Pollards
Wood Research Station, Chalfont St. Giles,
Bucks.
The distribution of benzo(a)pyrene (BP)-
DNA adducts within mammalian cell chro-
matin was examined by micrococcal nuclease
digestion of nuclei from carcinogen-treated
cells. Friend erythroleukaemia cells, pre-
labelled with [14C]-dT, were treated with 3H-
benzo(a)pyrene-7,8 diol-9,10-epoxide (BPDE)
and a nuclear fraction prepared. Micro-
coccal-nuclease digestion of nuclei, harvested
immediately after treatment, indicated a
4-fold enrichment ofBP-DNA adducts on the
linker region between nucleosome cores.
Analysis of DNA, isolated from briefly diges-
ted nuclei by agarose gel electrophoresis,
indicated that mononucleosomes released
early during digestion contained slightly more
adducts than total DNA. Treatment of pri-
mary mouse embryo cells with BPDE showed
a similar enrichment of BP-DNA adducts
within the linker region, however treatment
of such cells with BP for 72 h (necessary to
allow metabolic activation) showed no such
preferential location. This apparent difference
between the 2 agents was resolved by
showing that post-treatment incubation of
BPDE-treated cells led to a loss ofthe prefer-
ential linker binding. The time-dependent loss
of preferential binding was shown to be
independent of DNA replication, since it also
occurred when hydroxyurea, an inhibitor of
DNA synthesis, was present during post-
treatment incubation of the confluent cul-
tures.
MEASURING AFLATOXIN ACTIVA-
TION IN LIVER SLICES AND BY
BACTERIAL MUTAGENESIS, AS AN
INDICATOR OF SPECIES SUSCEPTI-
BILITY. P. J. HERTZOG, S. C. BOOTH &
R. C. GARNER, Cancer Research Unit,
University of York
There is considerable species variation in
susceptibility to aflatoxin B1 (AFB) carcino-
genesis, which is reflected in the extent of
carcinogen interaction with liver DNA as
measured in in vivo studies (i.e. rat >hamster
>mouse). We have tested S-9 fractions of
uninduced liver from these species for AFB
activation in bacterial-mutagenesis assays,
which are based on carcinogen-DNA inter-
action. Using S. typhimurium strains TA98
and TA100, hamster liver fractions produced
the highest number of mutants/plate, fol-
lowed by the rat and then the mouse.
When liver slices from these animals were
incubated in vitro with [3H]-AFB in an 02
atmosphere, the pattern of species suscepti-
bility was reflected in the level of binding of
[3H]-AFB to purified DNA (rat >hamster
> mouse :: 30: 11: 1). Preliminary data using
human liver slices indicates that DNA binding
of AFB is considerably less than in rats.
The limitations of using bacterial-muta-
genesis assays inthis study could bedue tothe
absence of cofactors for detoxification en-
zymes. Liver slices seem a reliable estimate of
the in vivo situation, at least with regard to
the level of DNA-bound AFB. One should be
careful, therefore, when interpreting data
from bacterial-mutagenesis screening; where-
as these latter systems provide a good indica-
tion of the mutagenic/carcinogenic potential
of a compound, they do not provide a good
indication ofpotency or species susceptibility.
INVESTIGATION OF THE BIOLOGI-
CAL EFFECTS OF TUMOUR PROMO-
TERS: INHIBITION OF METABOLIC
CO-OPERATION BY TPA. A. R.
KINSELLA, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, Man-
chester
It can be hypothesized that the phenomenon
of tumour promotion involves aberrant
mitotic segregation, which permits the ex-
pression of a specific recessive genetic or
epigenetic chromosomal change present in
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initiated cells (Kinsella & Radman, 1976,
Proc. Natl Acad. Sci. U.S.A. 75, 6149). In
favour of such a hypothesis we have demon-
strated that the anti-promoting agent anti-
pain inhibits MNNG-induced chromosome
aberrations in V79 cells, in the absence ofany
effect on MNNG-induced mutagenesis. Con-
versely, TPA enhances MNNG-induced chro-
mosome aberrations, in the absence of an
effect on MNNG-induced mutagenesis to
6TGR. There is, however, considerable contro-
versy surrounding the influence of TPA on
carcinogen-induced forward mutagenesis. A
comparison of in situ and replating muta-
genesis assay techniques in this laboratory,
has demonstrated that previous reports of
TPA enhancement of forward mutagenesis
were the result of a known artefact of the
in situ assay. Reconstruction experiments
show that the recovery of mutant colonies is
markedly reduced above a certain critical cell
density as a result ofspecific interclone meta-
bolic co-operation. Thus, mutant expression
is limited to the period between treatment
and attainment of the critical cell density.
TPA, by eliminating metabolic co-operation,
enhances mutant recovery in such systems in
the absence of any effect of mutagenesis per
se (Kinsella, Carcinogenesis, 2, 43). Compari-
son of the biological effects of the promoters,
anthralin, oleic acid, iodoacetic acid and
stilboestrol dipropionate with those of
TPA, seems to confirm that promoting agents
have no influence on mutagenesisper se. How-
ever, all these agents satisfy the requirements
ofthe hypothesis, ininducing eithernumerical
chromosomal changes or rearrangements.
DETECTION OF CARCINOGEN-DNA
ADDUCTS BY RADIO-IMMUNO-
ASSAY. R. SAFFHILL & J. M. BOYLE,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester
Certain butylating agents (e.g. butylnitro-
sourea and dibutylnitrosamine) are potent
carcinogens, but their reaction with DNA has
been little studied due to the limited specific
activity of the radioactive carcinogen avail-
able, the low level of reaction with cellular
DNA and the small amounts ofDNA extract-
able from some tissues of interest, or from
cultured cells. Some ofthese restrictions have,
sometimes, limited the study of the reaction
of methylating agents with DNA. We have
now developed sensitive radio-immunoassay
methods to detect specific butyl- and methyl-
adducts formed in DNA, in particular those
products that are potential promutagenic
lesions (viz. 06-alkyl-guanine, 02- and 04-
alkylthymine). Polyclonal antibodies have
been produced by immunizing rabbits or mice
with the appropriate nucleoside-protein con-
jugate. Mouse hybrid cell lines (hybridomas)
that produce monoclonal antibodies have been
made. These yield highly specific antibodies,
may be grown either in culture or as ascites.
cells in vivo and may be stored frozen to
provide a future source ofstandard antibody.
We now have a variety ofantibodies that are
specific for 06-butyldeoxyguanosine, 02
butylthymidine, 04-butylthymidine, 06-
methyldeoxyguanosine, 02-methylthymidine,
and 04-methylthymidine. Using a Farr
precipitation-inhibition assay we can detect
sub-pmd (<0-1 pmol) amounts of modified
nucleoside in the presence of,tmol amounts of
parent (unmodified) nucleoside. With these
radio-immunoassay methods it should be
possible to quantitate the levels of several
alkylation reactionproducts formed in cellular
DNA both in vivo and in vitro.
COLONIC LYMPHOID TISSUE AND
ITS INFLUENCE ON TUMOUR IN-
DUCTION IN DIMETHYLHYDRA-
ZINE-TREATED RATS. P. W. BLAND &
D. C. BRITTON, Department of Clinical Inves-
tigation, Royal United Hospital, Bath, and
Pharmacology Group, University ofBath, Bath
The mucosa of the large intestine contains a
large amount of organized lymphoid tissue,
but little is known of its contribution to
antigen-processing, secretory immunity or
tumour immunity. In the rat, mucosal lym-
phoid follicles are grouped together into dis-
crete colonic lymphoid patches (CLP) in the
proximal, mid and terminal colon. We have
investigated the relationship between CLP
and colonic neoplasia in the rat model of
1,2-dimethyl-hydrazine (DMH)-induced colo-
nic adenomas and adenocarcinomas.
100 male, 7-week old Sprague-Dawley rats
were injected s.c. with DMH (21 mg/kg)
weekly for 20 weeks and groups were autop-
sied from weeks 20-40. 52 rats bore a total of
71 colonic tumours. 57 (80%) of these tu-
mours (adenomatous polyps and both poly-
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poid and sessile adenocarcinomas) arose from
the epithelium overlying CLP, and many of
the remainder were closely associated with
isolated follicles.
Light and electron microscopy of CLP in
control rats showed that constituent follicles
were separated from the gut lumen by a
flattened lymphoepithelium, highly special-
ized to facilitate antigen transport. Adjacent
follicles were separated by groups of crypts
generating normal columnar epithelium. The
contribution to tumour induction in these
interfollicular crypts from altered epithelial-
cell kinetics and interaction with the under-
lying lymphoid elements. is currently under
investigation.
ANASTOMOSIS IS A FAVOURED
SITE FOR TUMOUR DEVELOPMENT
AFTER COLONIC SURGERY IN RATS.
J. B. BRISTOL, P. W. DAVIES, M. WELLS &
R. C. N. WILLIAMSON, University Department
ofSurgery, Bristol Royal Infirmary, Bristol
Metachronous colorectal cancer may develop
after partial intestinal resection because the
remaining mucosa is hyperplastic (Williamson
1979, R. Coll. Surg. Eng., 61, 341). This possi-
bility was tested in male Sprague-Dawley rats
(n=200) weighing 159 + 14 g (s.d.). Five
groups were subjected to either mid-colonic
transection, right or left hemicolectomy,
caecal resection or no operation (controls).
Operation was performed either before or
after 5-weekly s.c. injections of azoxy-
methane (10 mg/kg/wk) or vehicle.
Final tumour yields were unaffected by
timing of surgery. There was no evidence of
adaptive growth in the colon after partial
colectomy, though in the ileum wet weight
was increased by 22-40% after caecal resec-
tion or right hemicolectomy (P < 0-005). Of
the total of 217 large-bowel tumours, 23.5%
occurred at the colonic anastomosis, 40% in
distal colon, 20% in the rectum and 16.5% in
proximal colon. Left hemicolectomy reduced
the tumour yield by 52-88%, compared with
transection or controls (P =0.05-0.005). Cae-
cal resection had no effect. Although right
hemicolectomy produced a doubling in distal
tumours (P < 0-02) so did transection alone,
and in each group this is largely attributable
to the many anastomotic tumours. The
anastomosis was also the site for the develop-
ment ofaninvasive mucinous adenocarcinoma
at the colorectal anastomosis, following left
hemicolectomy in one rat receiving vehicle
alone.
Ileocolic and colorectal anastomoses are
favoured sites for tumour development after
partial colectomy. Unaltered carcinogenesis
in the remaining colon may reflect the lack of
adaptive change.
A COMPARISON OF RACIAL DISTRI-
BUTION OF CANCERS OF THE CER-
VIX AND PENIS AMONG 71 POPU-
LATIONS IN 28 COUNTRIES. I. K.
CROMBIE & T. M. SORAHAN. Cancer Epidemi-
ology Research Unit, Department of Social
Medicine, University of Birmingham
Populations predominantly of European des-
cent ("whites") experienced cervical-cancer
incidence rates which clustered tightly around
a median value 14-0 x 10-5. In contrast non-
white incidences were more evenly spread
about a higher median (22.4) and included
many higher rates. A similar pattern, at lower
incidences, emerged with penile cancer:
whites clustered around the median (0.7);
non-whites exhibited a wider range, a higher
median (1.05) and no clustering.
A highly significant correlation (P<0-001)
was found between the incidences of cervical
and penile cancer among all registries. Of all
the positive correlations between penis and
the 45 female sites and cervix with the 43
male sites the largest co-efficient was obtained
between penis and cervix; and no significant
correlation was observed with any other
genital site. Further examination revealed
that the penis-cervix relationship was almost
entirely due to the contribution of the "non-
white" populations, among whom a large
and significant (P<0-002) correlation co-
efficient was observed; the positive coefficient
among whites was small and non-significant.
The category "non-white" is a heterogeneous
collection of races. Subdivision into more
homogeneous groupings revealed a clustering
ofincidences: thus the Japanese in particular,
but other Asian groups as well, exhibited low
incidences of both cancers; whereas South
American populations, and those of African
descent, experienced a high incidence ofboth.
The marked correspondence between the
incidence of these cancers indicates related
aetiologies; possibly reflecting sexual mores or
hygiene practices.
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SOME EPIDEMIOLOGICAL ASPECTS
OF TESTICULAR CANCER IN ENG-
LAND AND WALES. J. M. DAVIES,
Division of Epidemiology, Institute of Cancer
Research, Sutton, Surrey
In 1901 testicular cancer was a rare disease
in this country, and death rates showed a
typical peak in old age. Since then incidence
and mortality rates among young men have
risen dramatically and now show a marked
peak around age 30; rates are still rising.
Successive birth cohorts of men born from
1871 to 1951 had steadily increasing death
rates up to age 45, and today testicular cancer
is the commonest neoplasm registered among
men aged 20-34. The disease is becoming
more common in Western countries generally
(especially in Denmark), but little is known
about its aetiology or the reasons for the
increasing incidence.
In 1971 mortality was highest among pro-
fessional, administrative and clerical workers
and lowest among manual workers, but dif-
ferential social-class rates were already
apparent in 1921 and 1931. U.S.A. data also
show the disease to be most common among
professional men. National mortality data
covering 1957-61 suggest that testicular
cancer is more common among single than
married men, but evidence from the U.S.A.
on this aspect is conflicting, and further
research is needed.
EPIDEMIOLOGY OF INDUSTRIAL
BLADDER CANCER IN WEST YORK-
SHIRE. R. A. CARTWRIGHT, Yorkshire
Regional Cancer Organization, Cookridge Hos-
pital, Leeds; R. W. GLASHAN, Urology Depart-
ment, Huddersfield Royal Infirmary
This paper presents some preliminary results
from a case-control study currently underway
in parts of West Yorkshire. To date 1015
cases and 1288 controls have been analysed.
Of these 72 cases and 37 controls were
employed for at least 6 months in the
chemical industry, giving a maximum-likeli-
hood estimation of the risk ratio as 3-1 (95%
confidence limits of 1-9-3-8). Other trades
whose work brought them into contact with
the chemical industry have an excess of
bladder cancer cases amongst them, at a
ratio of 2-5. Process workers associated with
the dye-manufacturing industry, who form a
substantial proportion of chemical workers,
have a higher risk still of bladder cancer
(4.5).
The case-control interviewing approach of
this study makes it possible to estimate how
other determinants of bladder cancer influ-
ence the risks for such hazardous occupations.
Process workers who smoke have a risk ratio
of nearly 6 whilst non-smoking process work-
ers have a lower and statisticallyinsigniificant
risk.
A COMPARATIVE STUDY OF THE
ANTITUMOUR ACTIVITY OF N-
METHYLFORMAMIDE AND RE-
LATED COMPOUNDS. S. P. LANGDON*,
N. W. GIBSON*, J. A. HICKMAN*, A. GES-
CHER*, M. F. G. STEVENS* & G. ATASSIt,
*C.R.C. Experimental Chemotherapy Group,
University of Aston, Birmingham; tInstitut
Jules Bordet, 1000 Brussels, Belgium
N-Methylformamide (NMF, HCONHMe) was
first reported to be active against the Sar-
coma 180 tumour in 1953 (Clarke et al.,
Proc. Soc. Exp. Biol. Med., 84, 203) and more
recently has been found to be active against
several human-tumour xenografts in mice.
Renewed interest in NMF, and our interest
in other antitumour agents with N-methyl
groups which are important for biological
activity has led us to investigate the activity
ofNMF, and someanalogues, against tumours
which are sensitive to the N-methyl group,
requiring drugs such as hexamethylmelamine
(HMM), DTIC and procarbazine. The M5076
ovarian carcinoma is one of the few murine
tumours which is sensitive in vivo to HMM,
and is also claimed to be an excellent model
for the prediction of chemosensitivity in man
(Simpson-Herren et al., 1979, Proc. Am.
Assoc. Cancer Res., 80) 106 M5076 cells were
implanted i.m. in the hind legs of 20g female
BDF1 mice and drugs administered i.p. daily
as a single dose from Day 1 to Day 17.
Tumour-volume inhibition on Day 24 was
100% for NMF, 64% for formamide (F) and
24% for N-ethylformamide (NEF) all at
300 mg/kg. Similar structure-activity rela-
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tionships had been reported by Clarke et al.
using the Sarcoma 180 and were confirmed by
us, using this tumour. TLX5 lymphomas
(105 cells s.c., drugs i.p. as a single dose on
days 3-7) which were either sensitive or
resistant to DTIC and procarbazine, both
gave 85% increase in survival time with
400 mg/kg NMF, but F and NEF had no
significant activity at this dose, again con-
firming the requirement for the N-methyl
group for significant in vivo antitumour effect.
METABOLIC STUDIES ON THE ANTI-
TUMOUR AGENT N-METHYLFOR-
MAMIDE. D. Ross, A. GESCHER & J. A.
HICKMAN, CRC Experimental Chemotherapy
Research Group, Department of Pharmacy,
University of Aston, Birmingham
Of all the formamides tested by others and
by us against various murine tumours, N-
methylformamide (NMF) is by far the most
active. To test the hypothesis that the marked
difference in activity is caused by differences
in the metabolism ofthese agents, we investi-
gated the biotransformation of NMF and
N-ethylformamide (NEF) in male CBA CA
mice. Parent compounds and their metabo-
lites were identified by gas chromatography
using an N2-sensitive detector. Formamide
(F) was the major urinary metabolite of both
agents. When NMF and NEF were incubated
with mouse liver preparations (whole homo-
genate, 9000g supernatant, microsomes) at
varying substrate concentrations and in the
presence and absence of 02 significant meta-
bolism could not be detected.
We also investigated the influence of a
series of N-alkylformamides on tissue levels
of the endogenous non-protein thiolgluta-
thione (GSH). GSH has been suggested to
regulate the toxicity ofdrugs like Adriamycin
(Olson et al., 1980, J. Pharmacol. Exp. Ther.,
215, 450) and paracetamol. 400 mg/kg NMF
given i.p. to mice lead to a marked decrease
of GSH in the liver; by 59-8% 1 h after drug
administration, whereas equimolar doses of
other N-alkylformamides had no depleting
effect. The hepatic depletion of GSH by
NMF may be related to the hepatotoxicity of
NMF seen in an early clinical trial (Laird
Myers et al., 1956, Cancer, 9, 949).
EFFECT OF ALKYLATING AGENTS
AND OTHER DRUGS ON THE UP-
TAKE OF MELPHALAN (M) BY
MURINE L1210 LEUKAEMIA CELLS IN
VITRO. A. D. MARTIN, R. W. G. BEER.
A. G. BOSANQUET & E. D. GILBY. Department
of Medical Oncology, Royal United Hospital,
Bath
M is a standard drug in the treatment of
multiple myeloma. In recent years combina-
tion therapy with prednisolone has improved
the response rate and survival times of
patients, but addition of further cytotoxic
drugs to treatment regimens has produced
little significant improvement. With an
experimental technique adapted from Vistica
et al., 1978 (Mol. Pharmacol., 14, 1136) we
have investigated the effect ofthese and other
drugs on M transport in vitro, as it is possible
that changes in response to treatment may be
related to changes in the transport of M. We
have confirmed that M uptake is an active
process competitively inhibited by L-leucine.
In 36 experiments in amino-acid-free medium
the mean concentration of M taken up was
225 pmol/106 cells. High-pressure liquid
chromatographic analysis of the cell sap
showed that most of the drug is present as
free native M. The nitrosourea BCNU was the
only drug of33 tested (at 1 and 10 times their
approximate serum concentrations in man)
which stimulated the uptake ofM, and did so
by 76% after 30 min. However, methyl
CCNU, with a similar structure to BCNU,
depressed M uptake by40%. Incubation with
adriamycin, aminophylline, chlorpromazine,
activated cyclophosphamide, mustine, oua-
bain or vincristine produced a decrease of
20-35% in uptake of M. Transport was
reduced to a lesser extent by incubation with
chlorambucil, frusemide or indomethacin.
It is possible that the inhibition of M trans-
port by these drugs when used in combination
with M could reduce the effectiveness of a
multi-drug regimen.
EFFECT OF L-METHIONINE DEPRI-
VATION ON THE PROLIFERATIVE
ACTIVITY OF NORMAL AND LEU-
KAEMIC MARROW CELLS IN VITRO,
S, ERIDANI, B. SAWYER, S. VILLA & M.
TISDALE, Departments of Haematology and
Biochemistry, St Thomas's Hospital and
Medical School, London
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Following previous work (Tisdale, 1980, Cell.
Biol. Int. Rep., 4, 563) suggesting that some
tumour cells may have a high requirement for
methionine, which in addition to protein
synthesis is used for nucleic-acid methylation
and polyamine biosynthesis, a comparison
has been made between normal and leukaemic
marrow (obtained from patients with ALL,
AML and CML) with regard to the capacity
to incorporate methyl-3HdT into acid-in-
soluble material, after incubation in media
lacking L-methionine and supplemented with
L-homocysteine. A lower incorporation was
shown by leukaemic cells, than normal ones,
with a significant difference (P<0.05). Mar-
row cells of leukaemic patients in remission
behave as normal cells.
This difference is not due to inability of
leukaemic cells to synthesize L-methionine
from homocysteine, because an increased
incorporation can be seen in the presence of
homocysteine when methionine concentration
in culture becomes limiting. Further experi-
ments suggest that such high methionine
requirement might be due to a decreased
transport capacity by leukaemic cells: all
marrows show the same linear uptake for the
whole range of concentrations tested, but
the maximum uptake velocity is lower in
leukaemic cells. Restriction by different
means of the supply of methionine to leu-
kaemic cells might play a role in the control
of myeloproliferative disorders.
QUANTITATION OF CARCINOGEN-
INDUCED RESISTANCE IN RAT
HEPATOCYTES TO CYTOTOXICITY
BY ADRIAMYCIN IN VITRO. B. I. CARR,
City of Hope National Medical Center,
Duarte, California, U.S.A.
The hepatocytes from rats which were
treated with a variety of hepatocarcinogens
in vivo have been shown to develop resistance
to Adriamycin-induced cytotoxicity, as meas-
ured by an in vitro assay using trypan-blue
exclusion (Carr, BACR, 1980). In order to
determine the quantitative relationships be-
tween the amount of carcinogen and the sub-
sequent development of resistance, a single
dose of 2-acetylaminofluorene (AAF) was
injected into male Fischer F344 rats weighing
200-220 g, and 18 h later their hepatocytes
were harvested and placed in primary mono-
19
layer culture for a subsequent 24 h. Cell
viability was then assessed in plates which
contained Adriamycin and compared to that
in controls. It was found that a single injec-
tion of 5 mg/kg AAF could induce resistance
to Adriamycin (1.8 x 10-4M) when measured
after 24 h in culture. Less than 2-5 mg/kg or
more than 25 mg/kg of AAF failed to induce
comparable resistance. When the rats were
harvested sequentially after a single dose of
5 mg/kg AAF it was found that the carcino-
gen-induced resistance to Adriamycin cyto-
toxicity was no longer present 7 days after
injection. By contrast, 0 02% AAF given
continuously in the diet led to a stable resis-
tance that did not decrease with time.
Resistance to Adriamycin which is induced
by a single dose of carcinogen now permits
the design of experiments to examine the
quantitative and temporal relationships in
rat liver, between induction of resistance to
cytotoxicity and altered cell growth.
A MODEL RELATING DRUG TRANS-
PORT, PROLIFERATION-DEPEND-
ENCE OF CYTOTOXICITY AND THE
EMERGENCE OF RESISTANCE TO
THE CURRENTLY USEFUL ALKY-
LATING AGENTS (AA). J. E. BYFIELD &
P. M. CALABRO-JONES, University of Cali-
fornia, San Diego, California, U.S.A.
Using human T-lymphocyte clonogenesis
in vitro we have studied the effect of the
induction of proliferation (by PHA) on the
sensitivity of T-cells to AA killing. It was
found that resting cells are considerably more
resistant (>Do and >Do) to some agents
(melphalan (MEL), cis-platinum, HN2) than
cycling cells. No effect ofthe cell proliferative
state could be found for BCNU, Me-CCNU,
MitomycinC,Procarbazine,ACNUandX-rays.
The toxicity ofMEL was reduced by competi-
tion with normal amino acids, confirming the
work of others. This confirms that MEL is
probably taken up by amino-acid transport
carriers in normal human cells. Glucose-
containing drugs (e.g. chlorozotocin) and acti-
vated cyclophosphamide (phosphoramide
mustard) wereineffective againstthesemature
T cells, though cytotoxic against epithelial
cells in culture. The data is consistent with a
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model in which the clinically useful AA fall
into two distinct groups: (1) those drugs that
are water-soluble, effectively lipid insoluble
and whose entry into cells is (membrane)
carrier-dependent; (2) those drugs that are
lipid soluble or amphipathic (carrier-indepen-
dent, CID) and that enter cells by simple
diffusion. CID agents all show prolonged
marrow depression and generally reduced
therapeutic ratios. We believe this relates to
a greatlvreduced dependence onproliferation,
since these must also directly enter normal
resting (marrowandgut) stem cells. Themodel
permits a rationalization of several aspects
of AA anti-cancer activity including (new)
drug design.
ENHANCEMENT OF ANTITUMOUR
ACTIVITY BY H2-RECEPTOR AN-
TAGONISTS. M. COLLINS, Cancer Chemo-
therapy Department, Imperial Cancer Research
Fund, London.
The antitumour effect of razoxane (RZ) is
enhanced by pretreatment with the H2-
receptor antagonist cimetidine (Collins, 1980,
Br. J. Cancer, 42, 173). The specificity of this
enhancement on the Walker tumour was
investigated.
In rats pretreated with cimetidine, metia-
mide or ranitidine, the antitumour effect
seen in response to RZ was significantly
greater than in rats treated only with RZ.
A similar degree of enhancement was
achieved using equiactive doses of the 3
antagonists against gastric acid secretion in
the rat. None of the H2-receptor antagonists
showed significant antitumour activity. Pre-
treatment with an inactive analogue of
cimetidine gave no enhancement of RZ anti-
tumour activity.
Rats were pretreated with cimetidine be-
fore administration ofRZ, cyclophosphamide,
methotrexate or 5-fluorouracil; enhancement
ofantitumour activity was only seen with the
combination of cimetidine and RZ.
Some structural requirement or activity
shared by cimetidine, metiamide and raniti-
dine, and not by the inactive analogue,
appears to be necessary for enhancement of
RZ antitumour activity. The reason for the
specificity ofthis enhancement to RZ is being
investigated.
IMPROVING THE THERAPEUTIC
INDEX OF CYCLOPHOSPHAMIDE
(CY) IN IMMUNE-DEPRIVED ANI-
MALS BEARING HUMAN OAT-CELL
LUNG TUMOUR XENOGRAFTS. B. D.
EVANS, I. E. SMITH & J. L. MILLAR, Institute
of Cancer Research and Royal Marsden
Hospital, Sutton, Surrey.
It was established in 1978 that the lethal
effects of high-dose cyclophosphamide (400
mg/kg) could be offset by pretreatment with
low-dose CY (50 mg/kg) given 4 days before
(Millar & McElwain, 1978, Antibiot. Chemo-
ther., 23, 271). In contrast, experimental
murine tumours do not appear to be protected
by similar CY pretreatment (Millar et al.,
1980, Br. J. Cancer, 42, 485).
Human oat-cell lung tumour xenografts
grown in immune-suppressed mice have been
shown to have chemotherapeutic responses
which correlate closely with those in the
patient from whom the original tumours were
obtained (Shorthouse et al., 1980, Br. J.
Surg., 67, 715).
First, we demonstrated that it is possible
to protect immune-deprived mice similarly
to normal mice with CY pretreatment. Then
we used the xenograft system to test whether
CY pretreatment could be used to increase
the therapeutic index of CY by decreasing
normal tissue toxicity whilst maintaining the
anti-tumour effect.
Two groups of 8 CBA/lac immune-sup-
pressed mice with bilateral flank implanta-
tions of a human oat-cell xenograft were
treated with 300 mg/kg CY i.p., with or
without pretreatment with CY (50 mg/kg) 4
days earlier. At 8 weeks, 6 of the pretreated
animals remained alive (75%) compared with
none of the controls (0%). In the pretreated
group 10/13 tumours were in complete remis-
sion (77%) compared with 7 out of 12 in the
controls (58%). These results show that CY
treatment enhances the therapeutic ratio of
large-dose CY in this oat-cell xenograft
system, and this may have useful clinical
implications.
ENHANCEMENT OF THE RADIATION
RESPONSE OF HYPOXIC MAMMAL-
IAN CELLS IN VITRO BY A PLATI-
NUM CO-ORDINATION COMPLEX.
A. H. W. NIAS & M. LAVERICK, Richard
Dimbleby Department of Cancer Research, St
Thomas's Hospital Medical School, London
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It is well established that certain platinum
complexes of the cis configuration are potent
antitumour agents in their own right. We
now report the effect of the platinum com-
plex-cis dichloro bis (isopropylamine) trans
dihydroxy platinum IV (CHIP) given as a
pretreatment to X-irradiated cultures of
Chinese hamster ovary (CHO) cells and C3H
mouse mammary tumour cells in vitro. CHIP
was given as a 1 h pretreatment at 37°C with
varying intervals before X-irradiation under
aerated and hypoxic conditions. Schedules
involving 1, 3, 5, and 24h intervals between
drug and radiation in hypoxic CHO cells
gave enhancement ratios (ER) of 1-7, 1*9,
1 36 and 1D0 respectively. The extrapolation
numbers remained unaltered. A lh delay in
drug and radiation treatment of aerated
CHO cells gave a much lower ER (1 1) but
the extrapolation number was reduced. C3H
mouse mammary-tumour cells showed no
enhancement by CHIP of the response of
aerated cells to X-ray damage. Enhancement
was only found under hypoxia. A maximum
ER of 1-7 was obtained after a 1-3h delay
between drug treatment and radiation. By
5 h, ER was reduced to 1-14 and at 8 h there
was no evident enhancement of cell killing.
Under optimal conditions of drug and X-ray
(lh delay) the effect ofCHIP pretreatment on
hypoxic cells is manifested not only as a
decrease in Do, which is measured by ER,
but also as a reduction in the "shoulder
region" to a point where survival is identical
to that in aerated X-irradiated tumour cells.
These results emphasize the importance of
finding the optimal regimes of drug dose and
timing of the subsequent X-irradiation.
DNA CROSS-LINKING INDUCED BY
PENTAMETHYLMONOMETHYLOL-
MELAMINE IN VITRO. J. R. F. MUINDI,
C. J. RUTTY & K. R. HARRAP, Department of
Biochemical Pharmacology, Institute of Cancer
Research, Sutton, Surrey
Pentamethylmonomethylolmelamine (CB 10-
369) the primary product of oxidative N-
demethylation of hexamethylmelamine 7
(HMM) (Life Sciences, 1980, 26, 147) is toxic
to a number of tumour cell lines in vitro and
has antitumour activity in vivo. CB 10-369
inhibits the incorporation of thymidine into
DNA of L1210 and PC6 cells in vitro, though
only the PC6 tumour is sensitive in vivo.
Formaldehyde, which is one of the products
of chemical breakdown of N-methylolmela-
mines, similarly inhibits dT incorporation in
these two cell types. DNA cross-linking was
assayed by the alkaline-elution technique of
Kohn et al. (Meth. Cell. Res. 1979, 16, 309).
Both formaldehyde and CB 10-369 produced
extensive total cross-links in L1210 cells.
These cross-links were susceptible to treat-
ment with proteinase K, and are therefore of
the DNA-protein type. Formaldehyde, but
not CB 10-369, also induced DNA strand
breaks in L1210 cells. In contrast to mel-
phalan, no DNA-DNA cross-links were
observed up to 24 h after treatment with CB
10-369. Furthermore, the DNA-protein cross-
linking induced by CB 10-369 and formalde-
hyde could be completely reversed by semi-
carbazide. Despite the in vivo sensitivity of
the PC6 tumour, neither DNA-DNB nor
DNA-protein cross-links could be demon-
strated in these cells, using an equitoxic con-
centration of the N-methylolmelamine. For-
maldehyde, however, did produce DNA-
protein cross-links in PC6 cells, and these were
again reversed by semicarbazide. Thus it
would appear that the antitumour action of
N-methylolmelamines is not attributable to
DNA cross-linking.
EXPERIMENTAL STUDIES ON TRI-
METHYLTRI METHYLOLMELA-
MINE AS AN ALTERNATIVE TO
HEXAMETHYLMELAMINE (HMM)
AND PENTAMETHYLMELAMINE
(PMM). D. R. NEWELL, C. J. RUTTY, J. R.
F. MUINDI & K. R. HARRAP, Department of
BiochemicalPharmacology, Institute of Cancer
Research, Sutton, Surrey
HMM is an established anticancer drug which
has shown activity against ovarian car-
cinoma, lung carcinoma and certain lym-
phomas. PMM, a water soluble alternative
to HMM, has recently undergone a number
of Phase I trials which, however, failed to
demonstrate complete or partial responses in
man (Proc. Am. Ass. Cancer Res., (1980)
21, 136, 143, 178, 347). It is postulated that
the relatively slow metabolism of PAM to
N-methylolmelamine in man fails to generate
therapeutic levels of these highly cytotoxic
species. In contrast, in the rat and mouse,
more rapid metabolism allows cytotoxic
levels ofthese metabolites to accumulate. The
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direct administration of an N-methylol-
melamine would circumvent the requirement
for metabolic activation.
For this reason we have studied N2, N4,N6-
trimethylol-N2,N4,N6-trimethylmelamine(CB
10-375). This compound has similar anti-
tumour activity to HMM and PMM against
a number of experimental tumours, whilst
CB 10-375 induces less neurotoxicity than
PMM in rats and mice. Pharmacokinetic
studies have demonstrated that CB 10-375
administration, to rats and mice, produces
higher peak plasma concentrations of N-
methylolmelamines (rat=450 ,uM, mouse=
740 ,uM) than does PMM (rat=225 ,tM,
mouse=575 ,uM). By analogy, the administra-
tion ofCB 10-375 to man may similarly result
in raised levels of N-methylolmelamines,
which could then be sufficient for a thera-
peutic effect. In addition, a medium has been
selected (10mM NaHCO3) which stabilizes the
N-methylol moieties sufficiently to facilitate
clinical administration without exposing
patients to formaldehyde.
HYPERTHERMIA AND CYTOTOXIC
DRUGS-COMBINED EFFECTS ON
NORMAL MOUSE BONE MARROW
CFU-S. D. HONESS & N. M. BLEEHEN,
MRC Clinical Oncology and Radiotherapeutics
Unit, Hills Road, Cambridge
A limiting toxicity of several cytotoxic
agents whose tumoricidal effects are enhanced
by hyperthermia to the marrow. The
spleen-colony-forming unit (CFU-S) assay
of Till & McCulloch, measuring survival of
undifferentiated marrow stem cells, provides
one method of quantitating marrow damage,
and has been used in this work to assess the
effects of combinations of hyperthermia with
cytotoxic drugs on marrow function.
Modest whole-body hyperthermia was ad-
ministered to unanaesthetized, unrestrained
C3H/He mice by enclosing them in an
incubator with a fresh air supply. This treat-
ment rapidly induced a rectal temperature
of 41°C +0-2°C which was maintained for 45
min, and this alone caused no change in sur-
vival of stem cells. Drugs were administered
i.p. just before the start of heating. Un-
heated mice were left at room temperature.
Room-temperature dose response curves
for cyclophosphamide and BCNU, giving a
drop in survival of up to one decade were
obtained, assays being carried out at 2 and
24 h after giving the drug. It was found that
for cyclophosphamide at 200 mg/kg the
hyperthermia caused a 10-fold increase in
stem-cell killing at both times; for BCNU at
60 mg/kg there was a similar increase in
killing at 24 h, but only 3-fold at 2 h.
These data indicate the need for directly
comparable tumour-cell-killing data in order
to estimate the therapeutic ratio of the com-
bined treatments.
FLOW CYTOFLUOROMETRIC ESTI-
MATION OF RELATIVE ADRIAMYCIN
BINDING TO DNA AFTER HYPER-
THERMIA IN VITRO. S. H. CHAMBERS
& N. M. BLEEHEN, MRC Unit of Clinical
Oncology and Radiotherapeutics, Cambridge
A method has been devised to estimate the
relative amount ofAdriamycin (ADM) bound
to DNA in cells treated with pharmaco-
logically relevant doses in vitro. ADM is an
intercalating agent which interferes with the
staining of DNA by the fluorescent dye
ethidium bromide. Cells were treated with a
range of ADM doses from 0 to 10 ,ug/ml.
Staining was then performed with ethidium
bromide at 2-5 tg/ml in 0.1% tri-sodium
citrate. The resulting fluorescence distribu-
tions from isolated nuclei were measured
with a flow cytometer. It was found that
increasing ADM concentration reduced the
intensity of the fluorescence emissions, and
the results indicate that doses differing by
1 ,ug/ml can be resolved in this system, so
long as strict control conditions are adhered
to.
The method has been used to investigate
the effect of heat on the binding of ADM in
cells. The results show that there is greater
binding of ADM to DNA after 1 h at 43°C
than after 1 h at 37°C for drug doses from
1 to 30 ,ug/ml. Secondly, this increase may
be due to an increased rate of binding of
ADM, longer exposures at 37°C raise the ADM
levels which tended to approach those of the
43°C cells. This method has potential for
measuring low ADM levels in cells isolated
from tumours, and benefits from only requir-
ing small cell numbers.
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MODIFICATION BY MISONIDAZOLE
AND METRONIDAZOLE OF THE RES-
PONSE OF THE RIF-1 MOUSE SAR-
COMA TO CYTOTOXIC DRUGS. P. R.
TWENTYMAN & P. WORKMAN, MRC Clinical
Oncology and Radiotherapeutics Unit, Cam-
bridge
Studies have been carried out into the ability
of misonidazole (MISO) and metronidazole
(METRO) tomodifytheresponse oftheRIF-1
sarcoma to a range of cytotoxic drugs. Sur-
vival of clonogenic tumour cells 24 h after
treatment has been used as the primary assay
of tumour response, and growth delay has
been measured as a secondary endpoint. The
nitroimidazoles were administered by the
i.p. route at a dose of 2-5 mmol/kg and at
30 min before the cytotoxic drugs.
Little change in the response to melphalan
was brought about by MISO or METRO
pretreatment. For cyclophosphamide a reduc-
tion in the shoulder ofthe cell-survival curve
was seen with MISO pretreatment, the sub-
sequent curves being parallel. This finding is
in agreement with our previous growth delay
studies.
A much larger increase in sensitivity was
observed if MISO was given before CCNU or
chlorambucil. The effect appeared to be dose-
modifying by a factor of -2. The enhance-
ment of these two agents was much less for
METRO pretreatment than for MISO.
Our current investigations include a study
of changes in haemopoietic toxicity brought
about by the addition of nitroimidazoles to
cytotoxic drug treatment.
STRUCTURE-ACTIVITY RELATION-
SHIPS FOR THE ENHANCEMENT OF
THE ANTI-TUMOUR EFFECT OF
CCNU BY ELECTRON-AFFINIC
AGENTS. P. WORKMAN & P. R. TWENTY-
MAN, MRC Clinical Oncology and Radio-
therapeutics Unit, Cambridge
The radiosensitizer misonidazole (MISO) has
been shown to increase the in vivo effect of
some cytotoxic drugs against some trans-
plantable tumours, e.g. the nitrosourea
CCNU against the KHT sarcoma in C3H
mice (Sieman, Br. J. Cancer (in Press);
Twentyman, Br. J. Radiol. (in Press). Using
aregrowth-delay assaywith theKHTtumour,
we have compared the ability of a range of
electron-affinic agents to enhance the anti-
tumour activity ofCCNU. No regrowth delay
was seen with the electron-affinic agents
alone. Agents were given (usually i.p.) 30 min
before 10 mg/kg CCNU i.p. MISO (2.5 mmol/
kg=500 mg/kg) increased the regrowth
delay from about 1-5 to 3-5 days (compared
to about 8 days with 20 mg/kg CCNU alone).
Using a fixed dose df 2-5 mmol/kg, we exam-
ined a series of 2-nitroimidazoles similar in
electron affinity to MISO, but differing in
octanol-water partition coefficient (P) over
3 orders ofmagnitude (0-016-20). Those more
hydrophilic than MISO (P=0-43), including
desmethylmisonidazole, SR-2508 (i.v.) and
SR-2555 (i.v.), were inactive, whereas those
more lipophilic tended to be more active than
MISO. Two fairly lipophilic 5-nitroimidazoles,
nimorazole (P= 1.4) and metronidazole (P=
0.96), showed similar or greater activity,
despite their considerably lower electron
affinity. Two basic 2-nitroimidazoles, Ro
03-8799 and RSU 1047, similar in electron
affinity to MISO, had about the same activity
as MISO. We also tested, at maximum toler-
ated doses, a number of agents with electron
affinity much greater than MISO. Nitrofuran-
toin (50 mg/kg), duraquinone (250 mg/kg) and
menadione (32 mg/kg) had little or no acti-
vity; nitrofurazone (125 mg/kg) showed more
activity, but less than MISO. The microsomal
enzyme inhibitor SKF 525A (50 mg/kg)
markedly increased the effect of CCNU. It is
possible that the enhancement of CCNU
activity by high doses of lipophilic analogues
in vivo may be due in part to inhibition of
CCNU metabolism.
DISPOSITION KINETICS AND META-
BOLISM OF CB 1954 IN MICE AND
DOGS. R. A. S. WHITE & P. WORKMAN,
Department of Clinical Veterinary Medicine
and MRC Clinical Oncology and Radiothera-
peutics Unit, Cambridge
CB 1954 (2,4-dinitro-5-azirdinylbenzamide)
is highly selective against the Walker 256 rat
carcinosarcoma, but shows little effect on
other tumours (Khan & Ross, 1969, Chem-
Biol. Interact., 1, 27; Cobb et al., 1969,
Biochem. Pharmacol., 18, 1519). It also
has interesting radiosensitizing properties
(Stratford et al., 1981, in Press), but little is
known of the pharmacokinetics. We de-
veloped a novel HPLC assay for the rapid
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analysis ofCB 1954 and its principal metabo-
lites, and used itto compare pharmacokinetics
in mice and dogs. With an i.v. dose of 50
mg/kg in mice the kinetics in blood were
biphasic, with a distribution-phase t- of
4 min and elimination phase t' of 1-4 h.
Given i.p. (25-100 mg/kg) the elimination
t-was similar and the bioavailability (AUC
i.p./AUCi.v.) wascomplete. Indogs theplasma
kinetics at 10-25 mg/kg i.v. were mono-
phasic, with a tI of3-4 h. After oral adminis-
tration in gelatin capsules the elimination
t' was similar and the oral bioavailability
(AUCoral/AUCi.v.) was50%. Inmice, urinary
excretion of unchanged drug was 20%. In
both species circulating concentrationsgreatly
exceeded those required to inhibit growth of
Walker tumour cells in vitro. Concentrations
of CB 1954 in EMT6 mouse tumours were
identical to those in blood from 2 h onwards.
Brain levels were half those in tumour
throughout. Repeated doses of CB 1954 (30
mg/kg/day i.p. x5) had no effect on the drug's
kinetics in mice; phenobarbitone (80 mg/kg/
day i.p. x 5) decreased the t- by 10%, and
increased the rate of aziridine-ring removal,
without affecting nitroreduction. The xan-
thine-oxidase inhibitor allopurinol (32 mg/kg
i.p.) did not alter CB 1954 levels in mice, but
appeared to delay the excretion of the nitro-
reduction product; the protective compound
phenylAIC (100 mg/kg i.p.) had no effect.
CORRELATION OF CYTOSINE ARAB-
INOSIDE (ARA-C) PHARMACOKIN-
ETICS, ARA-C PHOSPHORYLATION,
INTRACELLULAR ARA-CTP HALF-
LIFE AND EFFECTS ON DNA SYN-
THESIS IN ACUTE MYELOID LEU-
KAEMIA. A. L. HARRIS & D. G. GRAHAME-
SMITH, MRC Clinical Pharmacology Unit,
Radcliffe Infirmary, Oxford
Clinical resistance to Ara-C may be due to
short plasma 2-life, poor Ara-C phospho-
rylation or reduced sensitivity of DNA
synthesis to Ara-C in blasts in vitro. We have
measured Ara-C plasma levels after 2 mg/kg
bolus (Harris et al., 1979, Br. J. Clin. Pharma-
col., 8, 219) Ara-C phosphorylation to Ara-
CTP and inhibition of DNA synthesis by
Ara-CTP in intact blasts in vitro (Harris
et al., 1980, Br. J. Haematol., 45, 371). Ara-
CTP intracellular '-life was measured under
identical conditions. In 5 patients all these
measurements were performed before treat-
ment with Ara-C and daunorubicin. The
interaction of these variables could then be
simulated using the patients' in vivo and
in vitro data. Below 10 nm Ara-C there was no
effect on DNA synthesis in vitro. The area
under the plasma Ara-C concentration-time
curve (AUC until Ara-C fell below 10 nM) was
22-8-138 FLM/min. Ara-CTP production in
vitro was 0-015-0-6 1,mol/1012 blasts/min/I tM
Ara-C. 95% of maximal simulated Ara-CTP
production in vivo occurred by 45 min after a
bolus. Ara-CTP intracellular [-life was 30-120
min and 50% inhibition of DNA synthesis
was produced by 0-13-0-65 ,umol Ara-CTP/
1012 blasts. Simulated duration of >50%
inhibition of DNA synthesis was 4-14 h.
Simulations showed that increasing Ara-CTP
intracellular [-life from 30 to 60 min had a
greater effect on duration of inhibition of
DNA synthesis than a 5-fold increase in
Ara-CTP levels or a 5-fold increase in sensi-
tivity ofDNA synthesis to Ara-C. In patients
with low Ara-CTP levels 8-hourly i.v.
boluses produced more inhibition than the
same total dose by constant 24 h infusion.
These results explain the poor predictive
value of previously described variables, show
the importance of intracellular Ara-CTP [2
life, and suggest ways of optimising Ara-C
use in resistant patients.
POLICY OF MINIMAL INTERVEN-
TION IN THE MANAGEMENT OF
LOW-GRADE NON-HODGKIN'S LYM-
PHOMA OF THE FOLLICLE-CENTRE
CELL TYPE. C. MCCORMICK, R. C. F.
LEONARD, Oxford Lymphoma Group, Chur-
chill Hospital, Oxford
In a prospective study of non-Hodgkin's
lymphoma using the Kiel classification
(Gerard-Marchant et al., 1974, Lancet, ii, 406)
a group of60 patients with ML centroblastic-
centrocytic was selected for conservative
management. After biopsy and staging, 18
patients, including 12 with multiple-site
(Stage II-IV) disease were given no treat-
ment, a second group of 17 patients, including
9 withmultiple-site disease, localradiotherapy
for bulk disease, and a third group of 25
patients (all with multiple-site disease)
chemotherapy.
In the "no treatment" group 6 patients
eventually had radiotherapy and 5 chemo-
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therapy; 3 of these 11 have died. The re-
mainder are well between 22 and 52 months
from diagnosis. Six deaths (one with single-
site, 5 with multiple-site disease) occurred in
the radiotherapy group and 11 are well
12-55 months from diagnosis. Ten deaths
occurred in the chemotherapy group and 15
are well 14-58 months from diagnosis.
The actuarial survival projected for the
whole group is 63%, which is not inferior to
published reports of similar patients treated
more aggressively with the intention of
eradicating disease.
PHARMACOKINETICS OF SUBCU-
TANEOUS CYTOSINE ARABINOSIDE
IN PATIENTS WITH ACUTE MYELO-
BLASTIC LEUKAEMIA: M. L. SLEVIN*,
E. M. PIALLt, G. W. AHERNEt, A. JOHN-
STONt, M. C. SWEATMAN* & T. A. LISTER*.
*Imperial Cancer Research Fund Dept of
Medical Oncology, St Bartholomew's Hospital,
London: tDivision of Clinical Biochemistry,
Dept of Biochemistry, University of Surrey:
IDept of Clinical Pharmacology, St Bartholo-
mew's Hospital, London
The pharmacokinetics of s.c. (Ara-C) were
compared with bolus i.v. injection and i.v.
infusion in 5 patients with AML.
Ara-C plasma levels were measured by the
radioimmunoassay developed by Piall et al.
(Br. J. Cancer, 1979, 40, 548). S.c. Ara-C was
rapidly absorbed with a half-life ofabsorption
of 3-36 + 0 95 min, and then declined bi-
exponentially with a mean initial half-life
of 15-6 + 4-8 min, and a mean terminal half-
life of 16+0 1 h.
Following i.v. bolus administration Ara-C
declined triexponentially, with the initial
phase being divided into two exponentials.
The mean half-life of the first phase was 1 92
+0-28 min, the intermediate phase 14-1 +
1-3 min and the terminal phase 8-5 + 3.7 h.
(Erratic values were obtained from 2 patients
during the terminal phase and these gave rise
to the large mean terminal half-life).
Levels were above the steady-state infusion
levels for only 40 min after the i.v. bolus and
for 100 min after s.c. administration.
The decline in Ara-C was rapid after both
routes of administration, and after 5 h levels
were 10% of the steady-state infusion
levels.
The results of this study demonstrate that
it is not possible to achieve comparable
steady-state levels of Ara-C with the same
total dose given by s.c. bolus and by con-
tinuous i.v. infusion.
A PHASE I AND II STUDY OF m-
AMSA IN ACUTE LEUKAEMIA. M. L.
SLEVIN*, M. S. SHANNONt, H. G. PRENTICEt,
A. J. GOLDMAN* & T. A. LISETR*, *Imperial
Cancer Research Fund Department of Medical
Oncology, St Bartholomew's Hospital, London:
tAcademic Department of Haematology,
Royal Free Hospital, London
32 patients with relapsed or resistant acute
leukaemia were treated with m-AMSA at
doses ranging from 50-150 mg/M2 daily for
5 days.
Complete remission was achieved in 3/18
patients with AML, 2/9 patients with ALL
and 0/5 patients with CML in blast crisis.
In addition, partial remission was noted in
6/18 patients with AML, 4/9 patients with
ALL and 2/5 patients with CML blast crisis.
The complete remissions all occurred at or
above 100 mg/m2/day.
Haematological toxicity occurred in all
patients and was dose related. Nausea
and vomiting occurred in 8/26 courses at 50
mg/M2 and 12/18 courses at 150 mg/M2, but
were generally mild and easily controlled.
Alopecia was uncommon at the lower doses,
but occurred in all patients receiving the
higher doses. Stomatitis was noted in only
2/26 courses at 50 mg/M2 but in 8/16 courses
at 150 mg/M2. Mild and transient elevation
ofliver enzymes was common. No evidence of
renal failure or neurotoxicity was seen.
m-AMSA is an active drug in acute leu-
kaemia, with acceptable toxicity. Its place
in combination chemotherapy is now being
explored.
AMINOGLUTETHIMIDE IN ADVANC-
ED BREAST CANCER: EFFECTS OF
DOSE ON HORMONE LEVELS AND
RESPONSE. A. L. HARRIS*, M. DOWSETTt,
I. E. SMITH*, S. JEFFCOATEt, *Royal Marsden
Hospital, Fulham Road, tChelsea Hospital for
Women, London
Aminoglutethimide (AG), combined with
hydrocortisone, is a useful drug in advanced
postmenopausal breast cancer. It inhibits
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adrenal steroid synthesis and peripheral con-
version ofadrenal androgens to oestrone. The
minimum effective dose is unknown, the usual
dose being 1 g/day, and side effects increase
with AG dose. We have therefore studied 28
consecutive postmenopausal patients with
advanced breast cancer and measured oes-
trone levels before treatment, and after 500,
750 and 1000 mg daily, with 20 mg hydro-
cortisone twice daily. Dehydroepiandro-
sterone-sulphate (DHEAS), the main adrenal
androgen, was also measured. Both hormones
were measured by radio-immunoassay. The
results are shown below:
Pretreatmer
Oestrone pM 155 + 92
% ofbaseline oestrone
DHEAS (Mm) 1-81 + 1-12
% ofbaseline DHEAS
exposed to vincristine, 5-fluorouracil and
methotrexate. Clinically achievable extra-
cellular drug concentrations and exposure
times were used, these being derived from
parallel human pharmacokinetic studies.
End points used for determining drug effects
were inhibition of incorporation of appro-
priate precursors into nucleic acids, reduction
of colony-forming ability and slowing of
population growth rate. Vincristine (10--9-
10-7M), was active by all these criteria follow-
ing a 24h exposure. In contrast, treatment
with 5-fluorouracil (up to 3-5x 10-6M) or
Daily AG dose (mg)
nt 500 750 1000
*113+60.9 *78+52 *74+44
42+ 18 43+ 19 41+ 20
2 *0-14+0-08 *0-15+0-13 *0-1+ 0.1
16+10-9 10+8 8+7
* P = < 0-01 by paired t test compared to baseline levels.
There were no significant differences between
500, 750 or 1000 mg/day AG in effects on
oestrone or DHEAS. 26 patients were assess-
able for response. 6/8 responders had oestrone
<40 pM but only 2/18 non-responders had
such levels (P<0-01). There was no difference
in DHEAS suppression. These results show
that increasing doses of AG above 500-750
mg did not suppress oestrone further, and
suggest that an extra-adrenal source of
oestrone is responsible for higher oestrone in
non-responders. AG could be combined with
an anti-oestrogen in this group of patients to
try and increase their response.
FAILURE OF CYTOTOXIC-DRUG
THERAPY TO REDUCE THE COLONY
FORMING ABILITY OF A HUMAN
BREAST-CANCER CELL LINE. H. W.
VAN DEN BERGt, R. CLARKE* & R. F.
MURPHY*, Dept. Therapeutics and Pharma-
cologyt and Biochemistry*, The Queen's Uni-
versity of Belfast
Prior to investigating possible interactions
between hormone and cytotoxic-drug therapy
using human breast-cancer cells growing in
vitro as a model, we have assessed the ability
of cytotoxic drugs alone to kill such cells.
Human breast-cancer cells (MCF-7) were
methotrexate (10-8-10-4M) for the same
period has little effect on colony-forming
ability, though DNA synthesis was markedly
inhibited. Inhibition of nucleic-acid syn-
thesis correlated with an initial cessation of
population growth, but within 3-12 days after
treatment control growth rate resumed.
Similar results were obtained if cells were
grown in medium containing dialysed serum.
Exposure ofMCF-7 cells to higher concentra-
tions of5-fluorouracil for 1 h produced a more
marked reduction in population growth rate
suggesting that extracellular concentrations
of this drug mimicking those achievable in
vivo following i.v. bolus injection, were more
effective than those pertaining to 24h infu-
sions. Nevertheless, both 5-fluorouracil and
methotrexate appear to exert a cytostatic
rather than a cytotoxic effect on MCF-7
cells.
SERUM FUCOSE IN STAGED
BREAST-CANCER PATIENTS. B.
CANTWELL, J. J. FENNELLY & C. RYAN,
Medical Oncology Service, University College,
Dublin and St Vincent's Hospital, Dublin,
Ireland
The concentration of protein-bound fucose
in the sera of 144 normal subjects and 56
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subjects with staged breast cancer was
measured, in order to determine whether
raised serum fucose levels in breast-cancer
patients reflected tumour stage.
The method used for measuring protein-
bound fucose in the sera was that of Dische
& Shettles as described by Winzler (1955,
Methods Biochem. Anal., 2, 294). Serum fucose
levels were compared with concomitant
estimate of CEA and ESR in breast-cancer
patients and a positive significant correlation
obtained.
When compared to normal subjects sig-
nificantly higher serum fucose concentrations
were found in breast-cancer patients, and
showed correlation with tumour stage (UICC)
but not specifically to axillary-node status.
In 6 of 7 patients with advanced breast
cancer who had had serial estimations of
serum fucose, a falling level was noted in
association with response to systemic treat-
ments.
These results suggest that significantly
high serum fucose levels occur in breast can-
cer and correlate with advancing stage of
disease but not with nodal status. Serum
fucose estimations are also of value in assess-
ing tumour stage and response to therapy in
breast cancer.
OESTROGEN-RECEPTOR STATUS
OF BREAST CANCER IMMEDIATELY
BEFORE CHEMOTHERAPY AND
RESPONSE TO TREATMENT. J. F.
STEWART, R. J. B. KING & R. D. RUBENS,
ICRF Breast Unit, Guy's Hospital, London
There is uncertainty whether oestrogen
receptor (RE) content influences the response
of advanced breast cancer to chemotherapy.
However, the several reports to date have
used RE results obtained before the adminis-
tration of endocrine treatment. It is possible
that this treatment could alter receptor
status and that this phenomenon could
account forthevarying results so farreported.
Consequently, we have undertaken a pros-
pective study in which REs have been
measured immediately before chemotherapy.
Patients who have had additive endocrine
therapy in the preceding 4 weeks are ex-
cluded. Twenty-one patients in this study are
so far available for analysis. The preliminary
results are as follows:
RE < 5fmolj RE > 5fmol/
mg protein mg/protein
Number 11 10
Objective responses 5 (45%) 4 (40%)
No change 3 (27%) 1 (10%)
Progressive disease 3 (27%) 5 (50%o)
These early results suggest that RE status
immediately before chemotherapy does not
influence the frequency ofresponse to chemo-
therapy, but this study continues.
CIS - DIAMMINEDICHLOROPLATI-
NUM (CDDP) BY INFUSION IN THE
TREATMENT OF ADVANCED HEAD
AND NECK CANCER. A. L. STEWART,
R. C. S. POINTON, P. M. WILKINSON, Dept.
of Radiotherapy and Oncology, Christie
Hospital, Manchester
The introduction of CDDP has added a
further active agent to the treatment of
head and neck cancer. The use of this agent
is, however, often accompanied by severe
gastrointestinal and renal toxicity. This may
complicate its use in patients with these
tumours, who are oftenoldand in poorgeneral
condition. In an attempt to achieve useful
tumour regression with acceptable toxicity,
we have been evaluating CDDP used as a
24h infusion of 100 mg/M2 in 41 saline at 3
weekly intervals. 23 patients have received a
total of 71 courses of treatment (range 1-7).
Allexceptonehadreceivedpriorradiotherapy,
and 17 had received prior chemotherapy with
one or more agents. 2 patients had only
received one course of CDDP and were not
considered assessable for response. No patient
achieved a complete response, but 9 (42%)
achieved >50% partialremission. Themedian
duration of partial response was 24 weeks.
Toxicitywasacceptable,withonlyonepatient
declining further treatment. No impairment
of renal function was seen after less than 6
courses of therapy, and although most
patients experienced some nausea and vomit-
ing, only 5 (22%) described this as severe.
This study has demonstrated that CDDP is an
effective agent with acceptable toxicity when
used as a 24h infusion in the management of
head and neck cancer. It should now be
considered for use as the initial chemotherapy
for recurrent head and neck cancer, and the
combined approach of radiotherapy with
CDDP should be evaluated as initial definitive
therapy.
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PHARMACOKINETIC EVALUATION
OF METHOTREXATE IN THE MAN-
AGEMENT OF ADVANCED HEAD AND
NECK CANCER. P. M. WILKINSON, A. L.
STEWART, J. MARGISON & R. C. S. POINTON,
Dept of Radiotherapy and Oncology, Christie
Hospital, Manchester: S. B. LUCAS, Dept
Medical Computation, Manchester University
Methotrexate (MTX) (100 mg/M2) was ad-
ministered as an i.v. bolus every 14 days to
47 patients with advanced head and neck
cancer. Tumour regression was observed in
24/47 (51%) and in 5 (10%) this was com-
plete. The median duration of response was
20 weeks; 2 of the complete responders are
alive and disease free 16 and 20 mths after
discontinuing drug therapy. Toxicity was
mild and acceptable, the commonest side
effect being mucositis, which was observed
in 12% of treatment cycles. There was a
significant correlation for both response and
toxicity with the area under the third phase
of the concentration-time curve, and an
inverse correlation between response and
urinary MTX excretion during the first 24 h
after drug administration. The metabolite
7-OH MTX was present in serum 2 h after
drug administration, and attained peak levels
at 6-8 h. No kinetic parameter could be
identified that significantly correlated with
either response or toxicity. Despite extensive
pharmacokinetic analysis it was not possible
to produce a reliable model that can identify
those patients most likely to benefit from
therapy.
TREATMENT OF ADVANCED HEAD
AND NECK CANCER; SYNCHRON-
OUS THERAPY WITH METHOTREX-
ATE AND IRRADIATION. R. C. S.
POINTON, A. L. STEWART, R. D. HUNTER
& P. M. WILKINSON, Dept of Radiotherapy
and Oncology, Christie Hospital and Holt
Radium Institute, Manchester
One option to improve survival in Stage III
and IV head and neck cancer is to increase
the efficacy of local irradiation by means of
drug therapy. There is evidence that Metho-
trexate (MTX) can act as a radiosensitizer
in addition to its known cytotoxic effects.
Fifty patients with head and neck cancer
(16% Stage III and 84% Stage IV) were
treated with radical irradiation (15-16 frac-
tions over 21 days, 4-0-52-5 Gy) concurrently
with MTX 100 mg/M2 per i.v. bolus (Days 0
and 14). The first 14 patients received one
dose, the remainder both. The minimum
duration of follow-up is 2 years. Complete
resolution of disease was observed in 24
patients (507%); 4 patients have subsequently
relapsed and died (10, 14, 15 and 29 mths),
and 1 is alive with disease (25 mths). Toxicity
included exaggerated skin reaction (30%),
increased mucosal reaction (36%), delayed
mucosal healing (50%) and myelo suppression
(18/86 courses, 1 fatal). Most exaggerated
reactions were predictable by pre-treatment
assessment and 24h serum MTX concentra-
tions, however in some this was unpredictable
and the precise explanation is at present
unclear. These results suggest that syn-
chronous therapy may be superior to radia-
tion alone, and this hypothesis is currently
being tested at this Institute by an appro-
priate clinical trial.
QUANTITATIVE ASPECTS OF COM-
BINED INFUSIONAL 5-FU AND
RADIATION IN ADVANCED CANCER.
J. E. BYFIELD, University of California, San
Diego, California, U.S.A.
Our clinic has evaluated infusional 5-FU
(72-120 h) coupled with coincident X-ray
therapy (XRT) on a fortnightly basis for
advanced epithelial cancers (head, neck,
lung, GI, and anus). The program is based
on pre-clinical studies which have shown that
5-FU and XRT are synergistic only when (a)
5-FU is present post-XRT for > 24 hours
and (b) the extra-cellular level of 5-FU is
>400 ng/ml (5 human tumour-cell lines).
Pharmacokinetic studies in humans have
shown that 5-FU catabolism can be saturated
at high 5-FU infusional loads and the serum
level then "set" by appropriate infusion
rates. Clinical limiting toxicity for 5-FU
changes from marrow depression to stomatitis
at infusion durations >72 h. The onset of
stomatitis can be closely predicted by the
serum 5-FU levels (on a concentration x time
basis). Phase 1-11 studies ofthis combination
in the above tumours are nearly complete
and suggest enhanced response rates and
duration of response in several epithelial
tumours. The programme is especially promis-
ing in its effects on squamous-cell cancers of
the head and neck, oesophagus and anus.
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In addition it can be combined with per-
manently implantable arterial infusion pumps
for localized infusions (liver, limbs, etc.). In
this programme marrow toxicity is seldom
a major problem, though idiosyncratic reac-
tions are occasionally seen. 72h infusions
appear ideal for combination with XRT.
A MODIFICATION OF MEGA-DOSE
METHOTREXATE THERAPY WITH
MINIMAL TOXICITY AND AP-
PARENTLY MAINTAINED THERA-
PEUTIC EFFICACY IN VARIOUS
MALIGNANCIES. S. M. CRAWFORD, J. A.
Cox & R. L. TURNER, Bradford Royal
Infimary, Bradford
Methotrexate (MTX) therapy in the dose
range 1-10g/M2 was introduced in an attempt
to induce penetration of the drug across the
blood brain barrier and into large tumour
masses with poor vascularity. This dose of
MTX has usually been administered by i.v.
infusion over 4-6 h. Calcium folinate rescue
has commonly been started 4-6 h after com-
pletion of the infusion. Since MTX is S-phase
specific, this early reversal must mitigate
against its therapeutic effect.
In this study 130 courses oftreatment were
given to 26 patients. We have found that by
administering a dose of 1-5 g/m2 over 6 h
followed by calcium folinate rescue at 24 h
after the start of the infusion in patients
receiving intensive alkalinization of urine
over 3 days, haematological, hepatic and renal
toxicity were minimal. Serum MTX levels
were 1 Mm at 48 h in only 13 courses and in
most of these, further folinate rescue pre-
vented serious toxicity.
Best results were obtained in the non-
Hodgkin lymphoma, squamous-cell head and
neck carcinomas and neurofibrosarcoma. This
regime cost much less than conventional
high-dose MTX and folinic acid rescue.
A PROSPECTIVE RANDOMISED
STUDY OF CIS PLATINUM AS A
SINGLE AGENT AND IN COMBINA-
TION WITH CHLORAMBUCIL IN
ADVANCED OVARIAN CARCINOMA.
S. R. KANKIPATI & E. WILTSHAW, Institute
of Cancer Research, Royal Marsden Hospital,
London
Experience at the Royal Marsden Hospital
has shown that in patients with ovarian
cancer FIGO stages III and IV, together
with patients having recurrent disease follow-
ing radiotherapy, cisplatin+ chlorambucil+
Adriamycin is no better than cisplatin+
clhlorambucil. These patients now have more
than a 4-year follow-up.
From March 1979 to November 1980
inclusive 94 patients w%Nere entered into a
new study comparing chlorambucil +cis-
platin (Regimen B: cisplatin 20 mg/M2 i.v.
Day 1+chlorambucil 0-2 mg/kg/day p.o.
Days 2-8 for 12 courses) with cisplatin alone
(Regimen D: cisplatin 100 mg/M2 i.v. with
hydration for 5 courses followed by cisplatin
20 mg/M2 i.v. for 7 courses).
All good responders were subjected to
second-look laparotomy or laparoscopy. Com-
plete response rates were 22.9% for B and
15% for D, while overall response rates were
66.6% and 74%0 respectively.
The probability of surviving 12 months
was 570 and 35% at 24 months for both
regimens.
Patients with complete remission had
1000% survival after treatment B and 83%
after D at 22 months, whereas patients; who
had partial response had a survival of 450o
for B and 70%o for D at 22 months.
It is concluded that in the short term, D is
probably more effective than B but also inore
toxic.
SINGLE-AGENT CIS-DICHLORO-
DIAMMINE PLATINUM (II) IN
PREVIOUSLY UNTREATED PAT-
IENTS WITH OVARIAN CARCINOMA.
A. HOWELL, C. E. NEWMAN, K. K. CHAN,
G. D. NEWSHOLME, S. R. SMITH & R. A.
HURLOW. Departments of Medicine, Surgery,
Radiotherapy and Obstetrics and Gynaecology,
University of Birmingham, Queen Elizabeth
and Dudley Road Hospitals, Birmingham,
U.K.
Five courses of CDDP (100 mg/M2) were
given to 25 patients with Stages [Ib, Ill and
IV ovarian cancer. Eighteen patients had
second-look laparotomy at the end of treat-
ment and 7 were evaluated by clinical means
alone. In the surgical cases 6 (33%) had a
complete remission, 9 (50%) a partial remis-
sion and 3 (17%) had progressive disease.
After completion of surgery, 16/18 (890/) of
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patients were in complete remission. When
the 6 patients not operated upon were
included with the assessment of the surgical
cases after surgery, 19/25 (76%) had a com-
plete response. One patient could not com-
plete treatment because of tinnitus, and two
others developed a reversible peripheral
neuropathy. CDDP is highly active as a
single agent at this dosage in previously
untreated patients with late-stage ovarian
cancer.
TRIAL OF AN AROMATIC RETINOID
(AR) IN PATIENTS WITH SOLID
TUMOURS. G. J. S. RUSTIN & K. D.
BAGSHAWE, Department of Medical Oncology,
Charing Cros8 Hospital, London
Retinoids can inhibit growth of several
experimental tumours and stimulate differen-
tiation of mice embryonal carcinoma cells.
The effect of hypervitaminosis A induced by
an aromatic retinoid (RO 10-9359) was asses-
sed in 18 patients with advanced measurable
cancer. Patients received AR for a minimum
of 4 weeks. Hypervitaminosis A was judged
to be present when the patients exhibited
signs such as cheilitis, and was maintained by
25-50 mg of AR per day. All patients had
received prior cytotoxic chemotherapy, and
their types oftumour were metastatic testicu-
lar teratoma (6), ovarian adenocarcinoma
(4), metastatic melanoma (2), bronchial
adenocarcinoma (1), breast adenocarcinoma
(1), colonic adenocarcinoma (1), uterine
leiomyosarcoma (1), diffuse lymphocytic lym-
phoma (1) and Hodgkin's disease (1). There
was disease progression whilst receiving AR
in all patients except a female with lymph-
node metastases from ovarian adenocar-
cinoma, who had a marginal response for
2+ months, and in a female with cerebral
metastases from malignant melanoma. In
the latter patient there was no increase in
number or size of brain metastases whilst she
received AR for 9+ months. In the teratoma
patients 3 showed a rise in /3-hCG and 3 a
rise in AFP during AR therapy. One teratoma
patient had a laparotomy before and a
thoracotomy after 9 weeks of AR. Histology
showed similar undifferentiated tumour at
both operations. Although hypervitaminosis
A was well tolerated in these patients, it only
stabilized disease in 2/18 patients.
PRELIMINARY COMMUNICATION
ON THE PHARMACOKINETICS OF
HUMAN LYMPHOBLASTOID INTER-
FERON (HLBI) GIVEN BY I.M.
INJECTION. T. J. PRIESTMAN, M. D.
JOHNSTON & P. D. WHITEMAN, Wellcome
Research Laboratories, Beckenham, Kent
The object of this study was to monitor the
blood levels of HLBI over a 24h period in 4
patients with advanced malignant disease.
Interferon (IF) activity was measured in a
bioassay recording the degree of inhibition
of Semliki forest virus growing in V3 cells.
All patients received 4 to 5 Mu/M2 of Well-
come HLBI (sp. act. >4 x 107 u/mg protein),
2 patients had been given 2-5 Mu/M2 daily
for the previous 5 days and 2 had not received
IF for at least one week before. HLBI was
given by i.m. injection into the gluteus
muscle at 09.00. The pattern of response was
similar in all patients, peak blood levels
being reached at 4-6 h and declining there-
after with an apparent half-life of 12 h.
The relatively slow fall was probably mainly
due to continuing absorption from the i.m.
depot, and the true elimination half-life may
be much shorter. There was still some IF
present at 24 h, suggesting that daily dosing
might lead to some accumulation. This was
reinforced by the finding that the previously
treated patients had higher initial levels and
higher values throughout the study, peak
levels in these 2 being 300-350 u/ml compared
to 180 u/ml in the other 2 patients. In one
patient a sample of cerebrospinal fluid
showed no detectable IF activity at a time
when the blood level was 160 u/ml. The pat-
tern of response and blood levels seen in this
study are similar to those reported with
equivalent doses of leukocyte interferons.
RESULTS OF TREATMENT WITH A
MULTIPLE DRUG SCHEDULE (MDS)
IN26 PATIENTS WITH SOFT-TISSUE
SARCOMA. R. STUART-HARRIS, E. WILT-
SHAW, C. HARMER, A. MCKINNA & S.
CONINX, Royal Marsden Hospital, London
Between 1970 and 1980 26 patients with
advanced soft-tissue sarcoma were treated
with cyclophosphamide (600 mg/M2 max 1 g)
5-fluorouracil (500 mg/M2, max 1 g),Vin-
cristine (1 mg/M2, max 2 mg), actinomycin-D
(0-6 mg/M2, max. 1 mg) and methotrexate
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(200 mg). The methotrexate was given as a
24h infusion and followed by folinic-acid
rescue. Treatment wasrepeated every28 days.
5 patients had local disease, 21 had meta-
static or locally recurrent disease. There
were 2 complete and 5 partial responses
(overall response rate 27%). One complete
responder and 3 partial responders have
relapsed, average duration of response being
9 months. One complete responder remains
disease free more than 8 years after treatment.
Two partial responders have been converted
to complete remission, one with radiotherapy,
one with radiotherapy and surgery.
The regime is generally well tolerated,
though nausea, vomiting and thinning of the
hair may occur.
ROLE OF PULMONARY FUNCTION
TESTS IN THE PREVENTION OF
BLEOMYCIN PULMONARY TOX-
ICITY DURING CHEMOTHERAPY
FOR METASTATIC TESTICULAR
TERATOMA. H. H. LUCRAFT*, P. M.
WILKINSON & T. B. STRETTONt, *Christie
Hospital and Holt Radium Institute, Man-
chester, and tManchester Royal Infirmary
36 men were treated for metastatic testicular
teratoma with 4 courses of chemotherapy
each containing 90 mg bleomycin (BLM).
Routine pulmonary-function tests (PFTs)
were performed before each chemotherapy
course, to determine their value in detecting
early BLM pulmonary toxicity at this dose
level. PFTs were repeated 2-5 years after
completion of chemotherapy in 10 disease-
free survivors. Analysis of changes in indi-
vidual PFT values showed a fall in the carbon
monoxide diffusing capacity (DLco) after
90 mg BLM (P<0.002). The DLco remained
depressed with subsequent doses of BLM,
but there was no further statistically sig-
nificant fall. There was no statistically sig-
nificant change in any other PFT. Late PFT
values showed no significant change. There
were no cases of BLM pulmonary toxicity
detected. There was no correlation between
changes in the visible extent of metastases
as assessed from the chest radiograph and
changes in the PFTs. It was concluded that
routine PFTs are unnecessary if the total
BLM dose >360 mg, unless there are par-
ticular risk factors such as previous chest
radiotherapy or age > 70 years.
MANAGEMENT OF PSYCHOLOGICAL
STRESS IN CANCER PATIENTS:
AN ALTERNATIVE APPROACH. S.
BINDEMANN, K. C. CALMAN, R. A. V. MIL-
STED & J. M. TROTTER, Department ofClinical
Oncology, University of Glasgow
There exists at present no incontrovertible
scientific evidence that prognosis in the can-
cer patient is affected by emotional factors.
However, there is now considerable evidence
in support of the hypothesis that "quality
of life will be enhanced by intensive psycho-
logical support in the form of directive
therapy and antogenic training". (Simonton
& Simonton, 1975, J. Transper. Psych., 7, 29;
Meares, 1979, The Practitioner, 222, 119). A
group of cancer patients with advanced
disease who were all currently receiving cyto-
toxic chemotherapy were selected on the
basis of manifestly high anxiety reaction
and/or moderate to severe depression. All
patients admitted to the study had agreed to
procedures which had been carefully des-
cribed and explained to them. The value of
therapy was assessed subjectively by patients
and therapist. Objective evaluation was
attempted by means of questionnaire from
patients' relatives and from members of the
hospital's medical and nursing staff. Con-
sistently high levels of agreement were ob-
tained, which referred to rapid improvement
in patients' emotional state. This condition
was maintained without relapse in >80%
of all members of the group. Such results
suggest that therapy, which involves the use
of suggestion together with a degree of light
hypnosis, is ofvalue in relieving psychological
and psychosocial problems associated with
malignant disease. Further trials designed to
compare results obtained by this method,
with results obtained by means of similar
procedures involving psychophysiological
feedback techniques, are currently being
carried out as a stress-reducing adjunct to
primary cancer therapy.
NUTRITIONAL ABNORMALITIES IN
CANCER PATIENTS WITH WEIGHT
LOSS. J. M. TROTTER, P. BOYLE, J.
MCALLISTER, K. C. CALMAN & S. B. KAYE,
Departments of Clinical Oncology azd Bio-
chemistry, Gartnavel General Hospital, Glas-
gow, and Cancer Surveillance Unit, Ruchill
Hospital
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A group of 52 cancer patients with weight
loss (> 10% over 6 months or 5% over one
month) were assessed nutritionally by meas-
uring anthropometric data (mid-arm muscle
circumference, MAMC; triceps skin-fold thick-
ness, TSFT; weight and percent weight loss),
plasma proteins (albumin, total protein,
transferrin, pre-albumin, retinol-binding pro-
tein), serum vitamin A and plasma zinc.
Mean weight loss was 21.2%, with 53.1%
of patients having >20% loss of weight.
Mean survival in 44 deceased patients was
2-8 months, and only 6 patients in this
advanced-disease population survived >6
months. Patients were evaluated together
and in 3 groups: lung cancer (11), gut cancer
(18) and miscellaneous (23). There were no
significant differences between the 3 groups
with respect to age, sex distribution, anthro-
pometric data or plasma proteins. All subse-
quent data are therefore presented for the
group as a whole. Hypoalbuminaemia (82 7%)
and low retinol-binding protein (73-9%) were
common findings, as was low plasma zinc
(97.8%). Of interest is the lack of correlation
between those plasma proteins measured,
and also between the biochemical and
anthropometric data. In addition, none of
the tests of nutritional status, including
albumin, correlated with survival. It is
concludedthatinadvanced malignantdisease,
nutritional deficiencies are compound. An-
thropometric data alone provide an insuffi-
cient evaluation of nutritional status, and
selected vitamins and minerals also need
monitoring. The data also suggest that the
standard biochemical tests of nutritional
deficiency used for uncomplicated protein-
energy malnutrition, particularly plasma
protein measurements, are less applicable in
malignant disease. Further analysis using
these guidelines in patients with early disease
may provide information of therapeutic and
prognostic importance.
DIETETIC EVALUATION OF CANCER
PATIENTS. J. M. TROTTER, J. DUFFY,
K. C. CALMAN & J. C. WILLOX, Departments
of Clinical Oncology and Dietetics, Gartnavel
General Hospital, Glasgow
Nutritional deficiencies are common in the
cancer patient and abnormalities of carbo-
hydrate, lipid, mineral and vitamin metabo-
lism have been described (Theologides, 1979,
Cancer, 43, 2004). Biochemical screening for
all potential nutritional abnormalities is
expensive and often unrewarding. Manual
analysis of the composition of the diet is
tedious. In this study, a 24h dietary-recall
history was obtained from oncology out-
patients, and food composition was analysed
by a computer program based on the
McCance-Widdowson tables offood composi-
tion. Two groups were evaluated: those with
symptomatic anorexia and a second group,
who had not previously been seen by the
dietician, selected at random from the
outpatient population. A total of 59 patients
were assessed and 15 analyses were repeated
on a second occasion. Of the 33 patients
selected at random, 13 (39-4%) were eating
less than the recommended daily intake,
whereas this applied to all of the 26 sympto-
matically anorectic patients. Commonest food
aversions in the anorectic patients were
meat (11), tea (7) and coffee (4). Cravings
for cheese (5) and eggs (2) may represent
substitution of a more palatable protein
source for some patients. Dietary analysis
revealed frequent deficiencies of vitamins
(especially thiamine, B6, C, A and folic acid)
and of minerals (particularly Zn, K and Mg).
Computer analysis of food intake was found
to be rapid and easy and ofimmediate poten-
tial practical benefit, by pinpointing specific
dietary deficiencies. In addition, about 20%
ofasymptomatic patients were found to have
unsuspected dietary deficiencies.
SPINAL STABILISATION IN SEC-
ONDARY MALIGNANCY. A. J. BANKS &
C. S. B. GALASKO, Department of Orthopaedic
Surgery, University of Manchester, and E.
DERVIN, Department of Aeronautical and
Mechanical Engineering, University ofSalford
Back pain is commonly seen in patients with
malignant disease. In 10% of such patients
the pain is due to instability of the spine as a
result of the underlying bone destruction
(Galasko & Sylvester, 1978, Clin. Oncol., 4,
273). This complication is comparable to the
development of a pathological fracture in the
appendicular skeleton. Previous attempts to
stabilize the spine have only been partially
successful, because the apparatus used has
been designed for the stabilization of a
scoliotic spine.
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This paper describes the development of a
new rod which has been designed specifically
for the stabilization of malignant spines.
Preliminary laboratory tests have demon-
strated that the prosthesis should be in-
herently strong without the need for supple-
mentary cement or bone graft, and should be
fixed to the spine in an unstressed condition.
These criteria were met by using a square-
section bar which could be secured to the
spine at multiple levels.
To date 11 patients have been treated.
In all patients the extremely severe pre-
operative pain, which was exacerbated by any
movement, was relieved. Prior to surgery all
patients were confined to bed. Following
surgery they were all mobilized and could sit,
stand or walk without pain. Although some
of the patients have now died from their
disease, the longest survivor is still pain-free
and mobile two years after operation. All
patients achieved good palliation.
SELECTION OF METASTATIC
VARIANTS FROM N-METHYL-N-
NITROSOUREA-INDUCED RATMAM-
MARY TUMOURS. J. C. WILLIAMS, B. A.
GUSTERSON & R. C. COOMBES. Ludwig Insti-
tute for Cancer Research (London Branch),
Royal Marsden Hospital, Sutton, Surrey
N-methyl-N-nitrosourea (MNU) has been
used to induce mammary adenocarcinomas in
inbred strains of female rats; these tumours
are hormone sensitive but do not spon-
taneously metastasize (Williams et al., 1981,
J. Natl Cancer Inst., in press). Two methods
have been used to derive spontaneously
metastasizing tumours from MNU-induced
primaries.
A cell line has been isolated in vitro from a
mammary adenocarcinoma induced in female
F344/N rats. This strain of cells forms
colonies in lungs of syngeneic animals when
injected i.v., and forms tumours when
injected i.m., s.c. and into the mammary fat
pad. Tumours growing in these 3 sites show a
high incidence of metastasis to the lungs,
and in the lymph nodes at lower incidence. A
cell suspension obtained by enzymatic diges-
tion ofthe same initial MNU-induced tumour
formed lung colonies after i.v. injection.
Colonies were tested for metastasis after
reimplantation in the mammary fat pad.
After 3 passages through the lungs a solid
transplantable tumour has been obtained
which metastasizes spontaneously tothe lungs
and lymph nodes. The tumours formed by the
cell line and the transplantable tumours were
histologically similar, showing glandular dif-
ferentiation but including a spindle-cell
component and areas ofsquamous differentia-
tion. Metastases were morphologically similar.
Both tumoursandmetastases containmeasur-
able levels of cytoplasmic oestrogen receptor.
These systems may therefore constitute a
useful model for the study ofmetastasis.
EARLIER DETECTION OF CIRCU-
LATING TUMOUR CELLS AND
METASTASES IN A HIGH-META-
STASIS VARIANT OF LEWIS LUNG
CARCINOMA. M. MAGUDIA, P. WHUR, J.
ROBERTS & D. C. WILLIAMS, Cell Biology
Unit, Marie Curie Memorial Foundation,
Oxted, Surrey
A stable line of Lewis lung carcinoma was
maintained under a set of fixed conditions
i.m. passage of cells from pooled primary
tumours. A high-metastasis variant was
obtained by repeating the procedure but
substituting cells from lung metastases
(Magudia et al., 1980, Dev. Oncol., 4, 170) over
8 generations. In order to investigate the
difference in metastatic potential, mice
injected with one of the 2 lines were killed
daily in groups of 5 for the next 26 days and
the following parameters monitored: (1)
primary tumor size, (2) number and size of
overt metastases, (3) total and differential
WBC counts for quantitating circulating
tumour cells.
The primary tumours of the 2 lines grew
at the same rate (P>0-05) as did the meta-
stases (P>0-7). ByDay26 there were 134 + 12
metastases in the variant compared to 66 + 11
in the stable line (P<0-01). They appeared
5 days earlier (Day 5) in the variant and the
quantitative differences in metastases were
solely attributable to the time factor. Tumour
cells in venous blood were detected 8 days
earlier in the variant (Day 5) than in the
stable line. By Day 20 both had reached a
plateau of - 2 5 x 105 cells/ml of blood.
Our results suggest that the higher meta-
static potential of the variant is due to the
earlier establishment of metastases in the
lungs, which may in turn correlate with the
earlier appearance of tumour cells in the
circulation.
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PLOIDY DISTRIBUTION OF
TUMOUR CELLS FROM INDUCED
AND SPONTANEOUSLY ARISING
METASTASES. J. REEVE & P. TWENTY-
MAN, MRC Clinical Oncology and Radio-
therapeutics Unit, Cambridge
A radiation-induced sarcoma (RIF-1) of the
inbred C3H/Km mouse has been used in
studies designed to evaluate tumour-cell
heterogeneity with respect to a variety of
parameters including metastatic potential.
The tumour is non- or minimally immuno-
genic in its syngeneic host, and grows either
in vivo as a solid tumour or in vitro as a
monolayer, clones or, under appropriate
conditions, as multicellular tumour spheroids.
Flow-cytometric analysis of both in vivo-
and in vitro-derived tumour cells has shown
that the RIF-1 parent tumour is composed
of diploid and tetraploid sub-populations of
cells, each being capable of independent pro-
liferation. This finding has been confirmed by
chromosome analysis.
Following i.v. injection of 105 tumour-
derived cells into mice, artificial "metastases"
arise at a variety of body sites, including
lung, ovary and chest wall. Flow-cytometric
analysis of these "metastatic" sublines
revealed that, unlike the parent tumour, all
had a single level of ploidy, which remained
stable throughout 2 successive in vivo or
4 successive in vitro passages. Recently, data
have been obtained for the ploidy distribution
of spontaneously arising metastases after
removal of a large primary tumour. Early
results again indicate that these metastases
are composed of cells of a single level of
ploidy. This finding may indicate that, in
this tumour system, spontaneous metastasis
is a clonal event.
TUMOUR NECROSIS FACTOR FROM
THE RABBIT. IN VIVO ACTIVITY
AND SITES OF SYNTHESIS. N.
MATTHEWS, Medical Microbiology Depart-
ment, Welsh National School of Medicine,
Cardiff
Tumour-necrosis factor (TNF) was first des-
cribed byCarswell etal., 1975 (Proc.NatlAcad.
Sci, 72, 3666) as a factor present in the serum
of animals with shock induced by i.v. injec-
tion of BCG and endotoxin 2 weeks apart.
This serum induced necrosis of some trans-
plantable tumours and was cytotoxic in vitro
to certain tumour cell lines. As partially puri-
fied (x30) mouse TNF had both activities
it was suggested that the same factor was
responsible for both activities.
We have now shown that ,ug amounts of
rabbit TNF, purified 1000-2000 fold on the
basis of in vitro activity, can induce necrosis
ofa transplantable fibrosarcoma in mice.
The cellular source of TNF appears to be
the mononuclear phagocyte. Comparison of
various tissues from normal and BCG-injected
rabbits for capacity to synthesise TNF in
vitro has shown: (1) increased numbers of
mononuclear phagocytes in BCG rabbits;
(2) BCG-mononuclear phagocytes have much
increased TNF-synthetic capacity; (3) the
main sources ofTNF arelungs,liverandblood.
THE PRESENCE OF A TUMOUR PRO-
TECTS MICE UNDERGOING A GRAFT
VERSUS HOST REACTION (GVHR)
AGAINST THE ACTION OF LIPO-
POLYSACCHARIDE ENDOTOXIN
(LPS). D. B. PALMER, T. WHITMARSH-
EVERISS & M. 0. SYMES, Department of
Surgery, University of Bristol
(Ax CBA)F1 mice injected with A (immune
to CBA) spleen cells showed less GVHR (as
judged by spleen weight) if an F1 hybrid
tumour was present (Whitmarsh-Everiss &
Symes 1981, Br. J. Cancer, in press). Macro-
phage reactivity is increased in mice under-
going GVHR (Howard, 1961, Br. J. Exp.
Pathol., 42, 72) and such activated macro-
phages show increased sensitivity to the ac-
tion of LPS as judged by a rise in enzyme
levels after endotoxin administration (Ferluga
& Allison, 1978, Lancet, ii, 610; Bradfield
et al., 1980, Br. J. Cancer, 42, 900).
In groups of 4-6 F1 mice GVHR was in-
duced in the presence of an F1 tumour, after
tumour resection, or in animals not receiving
a tumour transplant. Thirteen days later,
halfthe animals in each group received 25 ,ug
LPS i.v., and all animals were killed 24 h later.
The plasma levels of amino aspartate trans-
aminase (AST) ornithine carbamoyl trans-
ferase (OCT) and f-galactosidase were deter-
mined. Injection of LPS produced a rise in
AST and OCT levels in all groups of animals.
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Enzyme levels (iu/1)
t AA
No tumour
GVHR
Tumour+GVHR
Tumour resected+GVHR
AST
76-7 + 28-6
231-7 + 31-2*
140-0+ 35-0 NS
373-7 + 35.0*
OCT
11-86+ 1-56
13-65 + 2-20 NS
3-91 + 2-20**
14-75 + 2-70 NS
-galactosidase
0-16 +0-04
0-45+ 005*
0-27 + 0-06 NS
0-51 + 0-06*
Sig vS No tumour: *P<0-001; **P<0-01. NS =Not significant.
In the animals receiving LPS, GVHR was
associated with a rise in the level of all 3
enzymes. The enzyme levels were reduced
when GVHR was ongoing in the presence ofa
tumour, an effect abolished by resection of
the tumour before the GVHR arose.
SPECIFIC AND NON-SPECIFIC CEL-
LULAR RESPONSES MODULATING
GROWTH OF RAT HEPATOMA
D192 AND THEIR MANIPULATION
IN IMMUNOTHERAPY. J. A. JONES,
G. ROBINSON & R. W. BALDWIN, Cancer
Research Campaign Laboratories, University
ofNottingham
The role of specific immune responses elicited
against tumour-associated antigens has been
evaluated using an aminoazo-dye-induced
hepatoma D192 transplanted into syngeneic
WAB/Not rats. Examination of the require-
ments of tumour-cell vaccines for generating
a specific tumour immunity demonstrated
that viable tumour cells admixed with BCG
so as to prevent progressive tumour growth
provided the most effective tumour-rejection
response. Under these conditions, effective
therapy could be initiated up to 6 days after
tumour challenge, so causing rejection of
tumour at a contralateral site. A major
component of the host response generated by
tumour-cell vaccines involved the production
of sensitized lymphocytes in the lymph nodes
draining the vaccine, since systemic anti-
tumour responses were abrogated by lympha-
donectomy. In contrast, removal ofthelymph
node draining the tumour-challenge site had
no effect. Lymphocytes stimulated by
tumour-cell vaccines transferred tumour im-
munity, this being specific for the immunizing
tumour. Vaccine treatment also leads to the
generation of natural killer cells, suggesting
that specifically sensitized effector cells are
necessary to elicit a tumour rejection res-
ponse, even though these cells may not be
directly cytotoxic.
20
SPECIFIC AND NON-SPECIFIC
LYMPHOCYTE CYTOTOXIC FUNC-
TION IN COLON CARCINOMA. P.
GALLAGHER*, B. M. VOSE, M. MOORE & P. F.
SCHOFIELD*, Department of Immunology,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, and *Department of
Surgery, Withington Hospital, Manchester
The cytotoxic activity of peripheral blood
(PBL), lymph node (LNC) and tumour.
infiltrating lymphocytes (TIL) from 47
patients undergoing surgery for colon car-
cinoma (Duke's Stage A, 1 patient; B, 24;
C, 15 and C with metastases, 7) was examined
in short-term Cr-release assays, against fresh
autologous tumour cells, allogeneic colon
cells and the erythroleukaemia cell line,
K562. Cytotoxicity against autologous cells
was detected in at least one effector popula-
tion in 23/47 (49%) patients, with ovedl
frequencies which did not differ significa4tly
for patients in different Duke's stages of
disease. By contrast, lysis of allogeneic
tumour cells was aninfrequent event ( < 11%)
regardless ofthe effector population to which
they were exposed. Cytotoxicity against
K562, cells highly sensitive to NK activity,
though variable, was detected in the PBL
of normal donors (93%) and patients (83 ),
and among the latter showed no evidence of
significant decline with advancing disease.
However, LNC and TIL anti-K562 activity
was detected only rarely (<17%), agreeink
with previous reports. There was no correlau
tion between the activity of patients' PBL
to lyse autologous tumour and K562 cells.
The independence of these 2 cytotoxic
functions was further explored in lymphocyte
fractionation studies: autologous tumour
killing was augmented in T-enriched PBL;
whilst greatest anti-K562 activity resided in
the corresponding non-T fraction. Lympho-
cyte cytotoxicity in colonic neoplasia is thus
manifest in 2 apparently independent
lymphocyte populations; a relatively specific
killer T-cell population, detectable in PBL,
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LNC and TIL, which is preferentially reactive
with autologous cells; and a non-specific killer
population, largely limited to PBL, with the
properties ofNK cells. The activity ofneither
population reflects the clinical status of
patients with this disease.
NK SENSITIVITY OF CELLS FROM
PRIMARY AND METASTATIC DE-
POSITS OF SPONTANEOUS TU-
MOURS. G. R. FLANNERY, C. G. BROOKS,
E. B. AUSTIN & R. W. BALDWIN, Cancer
Research Campaign Laboratory, University of
Nottingham
If natural killer (NK) cells play a role in
immunosurveillance it might be expected
that during the metastatic process, selection
would occur for tumour cells with reduced
NK sensitivity. This hyposthesis was tested
in the rat by measuring the NK sensitivity
of cells freshly isolated from metastases of 3
syngeneic transplanted spontaneous mam-
mary carcinomas. Lysis was measured in a
6h Cr-release assay using normal syngeneic
spleen cells as effectors. Cells from 6/13
draining lymph-node metastases and from
5/8 lung metastases were significantly (P<
0-01) less sensitive to syngeneic NK cells than
cells from the corresponding primary tu-
mours, but pericardial metastases showed
normal or raised sensitivity. Cold-target
competition assays indicate that the changes
in NK sensitivity ofmetastatic variants were
generally due to changes in intrinsic lysability
rather than in NK target structure, since
some of the most resistant preparations had
normal competitive activity. When placed in
culture, metastasis-derived cells regained
normal NK sensitivity within a few days.
These studies show that during metastasis,
selection for tumour cells expressing reduced
NK sensitivity can occur, and the tissue
distribution of metastases containing NK
resistant cells suggests that this takes place
primarily within the target organ rather than
at the site of the primary tumour or in the
blood stream. The results strengthen the
hypothesis that NK cells play a role in
immune surveillance, particularly in con-
trolling the metastatic spread ofcancer.
THE CYTOTOXIC ACTIVITY OF
TUMOUR-INTRINSIC AND PERI-
PHERAL-BLOOD LYMPHOCYTES
AGAINST AUTOPLASTIC COLOREC-
TAL CARCINOMA CELLS. D. HEINE-
MANN, G. H. HUTCHINSON, M. 0. SYMES &
R. C. N. WILLIAMSON, Department ofSurgery,
University of Bristol
Tumour digests were prepared using colla-
genase and DNAse, from 16 colorectal can-
cers. Neoplastic cells were separated by
centrifugation at 60 g for 10 min and tumour-
intrinsic lymphocytes (TIL) by passage of
the resulting supernatant through a nylon-
wool column. Lymphocytes were also separa-
ted from peripheral blood (PBL) by density-
gradient centrifugation, followed by passage
ofthe cells through a nylon column. The neo-
plastic cells were labelled with 100 ,Ci of
51Cr for 2 h, and then co-cultured with either
TIL or PBL for 2 h to determine lymphocyte
cytotoxicity.
In 11 of 16 patients PBL showed cyto-
toxicity, whereas in only 5/16 cases were TIL
reactive. However, in 11 casesthe cytotoxicity
of TIL was compared before and after wash-
ing the lymphocytes x 6 in Medium 199.
Cytotoxicity of unwashed TIL was found in
3/11 patients, whereas for washed TIL the
proportion was 9/11 (P<0 02). Furthermore
at the 10:1 and 20:1 effector target ratios
the level of cytotoxicity using washed cells
was greater (P<0-05 and P<0-001 respec-
tively). The greater cytotoxicity ofPBL than
TIL is correlated with a higher percentage of
T cells in the PBL population (50-6 + 15-5
vs 18-2+13-6; P<0-001). Washing of TIL
may remove tumour antigen which blocks
cytotoxicity (Currie & Basham, 1972, Br. J.
Cancer, 26, 427).
LYMPHOCYTE REACTIVITY TO
TUMOUR-ASSOCIATED ANTIGENS
OF HUMAN COLORECTAL CANCERS.
G. H. HUTCHINSON, D. HEINEMANN, M. 0.
SYMES & R. C. N. WILLIAMSON, Department
ofSurgery, University ofBristol
It has previously been found that lympho-
cytes separated from the tumour mass in
patients with colorectal cancer, show only
limited cytotoxicity on co-culture with 51Cr-
labelled autoplastic tumour cells. Lympho-
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cyte cytotoxicity was significantly increased
by washing x 6 in Medium 199.
In 5 patients with a benign polyp in addi-
tion to colorectal carcinoma, unwashed
lymphocytes from the polyp showed marked
cytotoxicity towards cells ofthe carcinoma.
Incubation of washed lymphocytes, ob-
tained from a carcinoma, in the patients' own
plasma significantly reduced their cyto-
toxicity (n=8; P<0.001). A similar reduction
was seen after incubation in plasma from a
second patient with colorectal cancer (n=6;
P<0001). Plasma from a patient with car-
cinoma of the breast also abrogated cyto-
toxicity, but the effect was significantly less
than for patients with colorectal cancer.
It is suggested that colorectal cancers
possess a common tumour-associated antigen
which blocks the cytotoxicity oflymphocytes
by coating their membranes. The antigen can
be removed by washing the lymphocytes. The
antigen is also shed into the plasma, hence
incubation of washed lymphocytes in same
plasma abrogates their cytotoxicity. The
antigen is present on the cells of polyps, but
is less readily shed, hence unwashed lympho-
cytes from a polyp react to a concomitant
carcinoma.
IMMUNE-DIRECTED THERAPY OF
A TRANSPLANTED RAT MAMMARY
CARCINOMA OF SPONTANEOUS
ORIGIN (SP4). J. A. JONES & R. W.
BALDWIN, Cancer Research Campaign Labora-
tories, University of Nottingham
A monoclonal antibody to a syngeneically
transplanted tumour has been used as a
carrier ofa chemotherapeutic drug, to investi-
gate its effect on in vivo tumour growth and
host survival.
Monoclonal antibodv (rat IgG2b, mouse
K chain) was isolated from hybridoma super-
natants by immunoadsorbent purification
(Sepharose goat anti-rat Ig) and conjugated
to Adriamycin via a dextran bridge. Sp4
tumour cells are susceptible to ADM in
vitro as shown by colony inhibition and
125IUdR uptake. In preliminary experiments
rats were implanted s.c. with 2x 104 Sp4
cells in admixture with 1 ,ug ADM either free
or conjugated to normal rat Ig or Sp4 MoAb
(drug:protein molar ratio - 15:1). Significant
inhibition of tumour growth by the drug-
MoAb conjugate was found.
Rats implanted s.c. with 2 x 104 Sp4 cells
were treated i.p. 7 days later with similar
conjugates, each rat receiving 10 ,ug drug
at a molar ratio to protein of 20:1; up to
3 more treatments were given weekly.
Tumour growth was retarded by free ADM
and drug-NIg relative to untreated controls
but the drug-MoAb group showed significant
tumour inhibition and increased survival
times. This was not seen when an irrelevant
spontaneous tumour (Spl5) was used.
These findings indicate that a monoclonal
antibody has potential in the systemic treat-
ment oftumour growth when used as a carrier
to therapeutic agents.
IN VIVO TUMOUR LOCALIZATION
OF MONOCLONAL ANTIBODY TO A
TRANSPLANTED RAT MAMMARY
CARCINOMA OF SPONTANEOUS
ORIGIN. M. V. PIMM & R. W. BALDWIN,
Cancer Research Campaign Laboratories, Uni-
versity of Nottingham
In view of the current interest in antibodies
as carriers of diagnostic and therapeutic
agents, studies have been carried out" to
examine the in vivo tumour-localizing poten-
tial of a monoclonal antibody (MoAb) to the
transplanted rat mammary carcinoma ap4
(Gunn et al., 1980, Int. J. Cancer, 26, 325).
Monoclonal antibody (rat IgG2b, mouse
K chain) was isolated from hybridoma super-
natants by immunoabsorbent purification
(Sepharose goat anti-rat Ig) and labelled
with 125J using Iodogen to luCi/,ug. On i.v.
injection into rats with pulmonary growths
of Sp4, labelled MoAb (0 5 pg/rat) showed
greater pulmonary uptake than with lungs of
normal rats, or rats with pulmonary growth
of an unrelated tumour (sarcoma Mc7). Up-
take of 125I normal Ig was not significantly
increased in Sp4-bearing lungs. In rats with
s.c. tumours, 125I-Sp4 MoAb (0.2 jug/rat)
showed a 2-6-fold higher uptake in Sp4
growths (0 6% injected activity/g) than in
lung, liver, spleen, kidney or heart (0-1-0.2%
uptake/g) and this was maintained over 5
days' observation. There was no increased
uptake into growths of other tumours (mam-
mary carcinoma Spl5, hepatoma D192A,
sarcomas Mc7 and Mc96A) and with 1251-Ig
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there was no more uptake into Sp4 growths
than with the other tumours.
These findings indicate that a monoclonal
antibody to a syngeneically transplanted
tumour has in vivo localizing potential, and
could be used for tumour detection and as a
carrier for therapeutic agents.
DEMONSTRATION OF ACTIVITY
OF MONOCLONAL ANTIBODIES
ON COLONIC TISSUE USING AN
INDIRECT IMMUNOPEROXIDASE
TECHNIQUE. R. M. GRANT*, P. J. FINAN*,
E. LENNOXt & N. M. BLEEHEN*, *MIRC
Clinical Oncology and Radiotherapeutics Unit,
Cambridge, tMRC Laboratory of Molecular
Biology, Cambridge
Immunoperoxidase staining techniques are
nowwidelyusedforlocalizing cellular antigen.
Methods previously described (Heyderman
& Munro Neville, 1977, J. Clin. Pathol., 30,
138) have used conventional antisera. The
introduction of monoclonal antibodies to this
technique may well allow for more specific
localization of these antigens.
Using an indirect immunoperoxidase tech-
nique we have screened 22 rat monoclonal
antibodies, isolated after immunization with
human colonic carcinoma membranes (Takei
& Lennox, unpublished), on 20 formalin-fixed
paraffin-embedded specimens of colonic car-
cinoma. Two distinct patterns ofactivity have
been noted. Three antibodies showed activity
on all normal colonic epithelium, both as an
intracellular granular stain and on the sur-
face of the epithelial cells, filling the goblets
and staining the mucus secretions. A further
2 monoclonal antibodies showed maximal
activity in colonic tumours, with apical intra-
cellular staining ofthe tumour cells and dense
staining in the lumen of malignant tumour
glands. This pattern of staining was present
in 19 of the 20 tumour specimens. Further
work isrequired to determine the exact nature
of antigens demonstrated by this technique.
The immunoperoxidase technique is a
suitable method for initial screening ofmono-
clonal antibodies on tissues of interest. As
more monoclonal antibodies become available
this technique will allow for better localiza-
tion oftumour antigens and potential marker
substances.
IDENTIFICATION OF ANTIBODIES
TO HUMAN PANCREATIC CANCER
CELLS IN IMMUNOCOMPETENT
HAIRY LITTER MATES IMMUN-
IZED WITH SERUM FROM TUMOUR-
BEARING NUDE MICE. A. G. GRANT,
D. DUKE & J. HERMON-TAYLOR, Department
of Surgery, St George's Hospital Medical
School, London, and the Department of Cancer
Chemotherapy, Imperial CancerResearchFund,
London
Using the concept that tumour cells synthe-
size and release specific membrane-associated
proteins during growth, antibodies have been
raised in immunocompetent hairy litter mates
to sera from nude mice bearing human pan-
creatic tumour. No antibodies were detected
in tumour-bearing nude-mouse serum. Anti-
sera raised against sera from 2 different
pancreatic cancer xenografts showed a titre
of activity > 1 625 against cultured pan-
creatic tumour cells by an 1125-binding assay.
Five out of the 14 hairy litter mates immun-
ized with serum from the same tumour
(GER) produced antisera that bound more
strongly to pancreatic cancer cells (binding
ratio >2) when tested against human foetal
pancreatic fibroblasts, normal and EBV-
transformed lymphocytes, myeloid, lympho-
blastoid, mammary and urinary bladder
human tumour cell lines, and a murine
tumour cell line. Binding ratios of <2 were
found with a fibroblast cell line derived from
the same pancreatic tumour (GF) and a colon
tumour cell line HT-29. Adsorption of the
antisera withCEAreducedthe levelofbinding
by 11-24% without affecting the specificity
for pancreatic tumour cells. Immunofluores-
cent staining of pancreatic tumour sections
indicated that the antibody was localized
on the membrane of ductular epithelial cells.
Challenge of immunocompetent mice using
this procedure may provide a route to the
production of antibody for the characteriza-
tion of selected tumour components.
LEVAMISOLE AS AN INHIBITOR
OF ENDOGENOUS ALKALINE PHOS-
PHATASE (AP) IN IMMUNOHISTO-
CHEMISTRY WITH AP CONJUGATES.
B. A. J. PONDER & M. WILKINSON, Institute
of Cancer Research, Sutton, Surrey
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We wished to use AP conjugates to demon-
strate H2 antigens in mouse tissue sections by
immunohistochemistry. A major difficulty
was to inhibit endogenous tissue AP without
interfering with the specific staining. Stan-
dard methods, such as exposure of sections to
20% acetic acid, destroyed the antigens we
hoped to demonstrate.
Levamisole (1-tetramisole) inhibits the
non-intestinal form of AP, but is without
effect on the intestinal form. We have
exploited this difference by using conjugates
made with calf intestinal AP. The AP stain-
ing is performed in the presence of 1 mmol/l
levamisole, whichinhibits endogenous enzyme
in all tissues other than small intestine and
stomach, without loss of specific staining by
the conjugate.
SEPARATION OF HUMAN BREAST-
CANCER CELLS. R. BUCKMAN, D. P.
DEARNALEY, R. C. COOMBES & A. M. NEVILLE,
Ludwig Institute for Cancer Research (London
Branch), Royal MVarsden Hospital, Sutton,
Surrey
We have developed a simple and reliable
rosetting technique to separate malignant
breast epithelial cells from host stromal cells
at various metastatic sites. The method has 3
applications.
(A) In order to increase the detection rate
of malignant cells in marrow, we have ob-
tained 6 aspirates from each patient. The
large number of smears generated prompted
us to develop a simplified screening procedure.
The monoclonal antibody anti-HLe-1 (gift
of Dr P. Beverley) (Bradstock et al., 1980,
J. Natl Cancer Inst., 65, 33) binds to most
normal marrow cells, which are then removed
by rosette formation. This method rosettes
out an average of9500 (range 85-98% N=10)
ofnormal marrow cells, leaving the malignant
cells in the layer which can then be examined
with only one or two smears.
(B) In order to free the marrow of small
numbers of malignant cells, we have used an
antiserum to epithelial membrane antigen
(Heyderman et al., 1979, J. Clin. Pathol.,
32, 35) to rosette out the malignant cells, and
are currently investigating the effect of this
procedure on marrow function in vitro.
(C) We have prepared pure tumour-cell
populations from digests of involved lymph
nodes removed at surgery. Using anti-HLe-l
and the anti-fibroblast monoclonal 86-3
(Edwards, 1980, Cell Biol. Int. Rep., 10, 917)
we have obtained 105-106 tumour cells from
6 nodes with no detectable contamination by
host cells.
We feel that rosetting techniques using
monoclonal and conventional antibodies may
be useful in cell separation for diagnostic and
other purposes.
PERIPHERAL-BLOOD INVOLVE-
MENT (PBI) IN LYMPHOMA: DE-
TECTION USING LECTIN BINDING.
G. BLACKLEDGE, A. MORRIS, D. CROWTHER &
J. GALLAGHER, CRCDeptofMedical Oncology,
Christie Hospital, Manchester
PBI in lymphoma may be difficult to detect
by morphological methods, since abnormal
cells may resemble normal peripheral-blood
lymphocytes (PBL). PBL have a characteris-
tic lectin-binding pattern using fluorescent
Concanavalin A (Con. A), Lens culinaris
Lectin (LCA) wheat-germ lectin (WGA)
and peanut lectin (PNA) when measured by
flow cytometry. The PBL ofover 60 patients,
13 with Hodgkin's disease and 47 with Non-
Hodgkin's lymphoma, have been studied
using lectin binding. The different histological
subtypes of disease showed characteristic
lectin-binding patterns which have enabled
recognition of PBI in these diseases. The
results suggest that even in cases where PBI
is unexpected, abnormalities may often be
found. No evidence was found for anincreased
PNA-reactivity or decreased sialic-acid levels
in malignant cells. Further investigation of
these abnormalities is continuing by correlat-
ing these findings with those using immuno-
logical surface markers.
NEUTROPHIL FUNCTION IN NEU-
TROPENIC PATIENTS. M. A. CORNBLEET
& G. A. CURRIE, Divisions ofTumour Immun-
ology and Medicine, Institute of Cancer
Research, Sutton, Surrey
Emission of light (chemiluminescence) during
phagocytosis by neutrophils is correlated
with increased glucose oxidation and the
generation of bactericidal excited oxygen
species (Allen et al., 1972, Biochem. Biophys.
Res. Comm.,47, 679). Addition ofthe nontoxic
cyclic hydrazide, luminol increases the light
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yield by several orders of magnitude permit-
ting areductionintherequirednumberofcells,
so that the response of neutrophils from pro-
foundly neutropenic patients can be assessed.
Thirty-one patients with disseminated solid
tumours who were neutropenic (total white
count < 109/1) as a result of chemotherapy,
were divided into 3 groups. Eight afebrile
patients had cheZniluminescence (CL) respon-
ses which did not differ from those of a con-
trol group of patients with normal white
counts. Seven febrile patients with antibiotic-
resistant, presumptively "non-bacterial"
fevers, also had normal CL responses, but 16
patients with proven or presumed bacterial
infection (antibiotic-responsive fevers) had
significantly more active neutrophils. Two
false-negative results occurred in this group,
while one false-positive occurred in both the
afebrile and the "non-bacterial" groups, the
latter in a patient with a Candida albicans
septicaemia. The overall misdiagnosis was
13%. Normal luminol-dependent CL activity
after a trial of antibiotics in the neutropenic
patient with a pyrexia of unknown origin,
should suggest that potentially toxic treat-
ment may safely be withdrawn, whereas
increased activity in the presence of an anti-
biotic-resistant fever might suggest a fungal
aetiology.
oil ANTITRYPSIN, A MARKER FOR
HUMAN REACTIVE AND NEOPLAS-
TIC MACROPHAGES. D. B. JONES, P.
IsAACsoN & K. M. HIGGINSON, University
Department ofPathology, Southampton General
Hospital
The classification of malignant lymphoma
has benefited greatly from the development
of immpunologically defined markers of cell
lineage. Thus with regard to lymphocytic
lymphoma, the malignant cell type can be
related to normal counterparts present within
the lymphocyte maturation sequence (Isaac-
son et al., 1980, J. Histochem. Cytochem., 28,
761)
Reliable markers for the identification of
tumours ofmacrophage origin have, however,
proved difficult to establish. Preliminary
studies in this laboratory have suggested
that oil anti-trypsin (cxl anti-T) is a useful
immunohistochemical marker of cells of the
monocyte-macrophage series (Isaacson et al.,
1979, Lancet, ii, 964). We have extended the
study of macrophage a,, anti-T to cultures of
normal human monocytes and to the histio-
cytic cell line U937 (Sundstrom & Nilsson,
1976, Int. J. Cancer, 17, 565).
Studies involving immunodiffusion and
isotopic labelling have confirmed that macro-
phage a, anti-T shows immunological identity
with al anti-T present in serum, and isoelec-
tric focusing suggests that this material is
synthesized by cells of histiocytic lineage.
Positive staining for this glycoprotein is
therefore a reliable marker for lymphoreticu-
lar neoplasms of histiocytic origin.
CORRELATION OF 3 TUMOUR
MARKERS (CALCITONIN, CEA AND
3-hCG WITH RESPONSE TO
THERAPY AND EXTENT OF DIS-
EASE IN SMALL-CELL LUNG CAN-
CER. A. P. SAPPINO, M. L. ELLISON, S. C.
CARTER & I. E. SMITH, The Royal Marsden
Hospital and Ludwig Institute for Cancer
Research (London Branch), Sutton, Surrey
Plasma levels of 3 tumour markers (calcito-
nin, CEA and P-hCG were measured at
presentation in 40 patients with small-cell
lung carcinoma, to investigate whether there
was any correlation with response to chemo-
therapy and extent ofdisease.
10 patients (25%) had raised calcitonin,
15 (38%) raised CEA and 7 (18%) raised
P-hCG levels. 20 patients (50%) had no abnor-
mal markers, 10 (25%) had one marker
abnormal and 10 (25%) had 2 or 3 abnormal
markers.
The response rate achieved with chemo-
therapy was related to the number of raised
markers: of the 22 patients who responded,
19 had 0-1 marker raised, whereas only 2
had 2-3 markers raised. Strikingly only 2 of
the 10 patients with high calcitonin responded
to therapy.
The extent of disease at presentation cor-
related with the number of raised markers:
15/30 patients with 0-1 marker raised had
extensive disease, compared with 8/10 with
2-3 markers raised. In particular 12/15 with
high CEA had extensive disease.
These results indicate that certain tumour
markers or combinations ofmarkers may help
to predict both response to therapy and
extent of disease in patients with small-cell
lung cancer, with important prognostic
implications.
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THE "HOT SPLEEN" PHENOMENON
IN ADVANCED MALIGNANT MELA-
NOMA. J. WAGSTAFF, K. PHADKE, N.
ADAMS*, N. THATCHER & D. CROWTHER,
CRC Dept of Medical Oncology, Christie
Hospital, *Dept of Diagnostic Radiology,
University Hospital ofSouth Manchester
Technetium-99M Sulphur Colloid liver scans
were performed in a series of patients with
advanced malignant melanoma (MM), (Stages
II and III) prior to treatment with immuno-
therapy or chemotherapy. Patients with
metastatic and non-metastatic liver disease,
anaemia, infection and diabetes mellitus were
excluded from the analysis. Review of 124
cases showed that 36% with Stage II disease
and 43.6% with Stage III displayed a "hot
spleen", with greater density of counts over
the spleen than the liver. The feature in-
creased in frequency with stage ofdisease, but
was not associated with a shorter disease-free
interval or worse survival. Others (Sober etal.,
POS
9,10-DIMETHYL - 1,2 - BENZANTHRA-
CENE (DMBA) AND 12-0-TETRA-
DECANOYL PHORBOL 13-ACETATE
(TPA) INDUCED CHROMOSOME
CHANGES IN PRIMARY CULTURES
OF MOUSE AND HUMAN EPIDERMAL
CELLS. J. BROADHEAD & A. R. KINSELLA,
Paterson Laboratories, Christie Hospital and
Holt Radium Institute, Manchester
The classical system for the study of 2-stage
carcinogenesis in vivo has been mouse skin.
Primary cultures of epidermal cells isolated
from neonatal BALB/c or SENCAR mouse
skin are being studied in vitro. Results from
this system are compared with those obtained
from human keratinocytes in vitro.
Chromosome changes have often been
implicated in the process of neoplastic trans-
formation. In vitro epithelial-cell systems
allow this process to be followed through the
stages ofinitiation and promotion, eventually
giving rise to fully transformed cells. It is
therefore possible to study chromosome
changes associated with the progression
towards malignancy. Primary mouse and
human epidermal-cell cultures were treated
1979, J. Nucl. Med., 20, 1232) have shown
a higher relapse rate in Stage I patients with
"hot spleens". The phenomenon was com-
moner in females than males and there was a
significant association with a high serum IgM
level (P=0.02).
The feature seems to be due to augmented
activity of splenic macrophages due to the
presence of tumour, possibly due to stimula-
tion by tumour-associated antigen, immune
complexes or both. It has resolved after sur-
gical excision of localized tumour (Klingen-
smith, 1974, J. Nucl. Med., 15, 1203) and its
persistence after primary excision of tumour
in Stage I patients may reflect the presence of
residual disease. As disease advances, macro-
phage function becomes impaired. This may
explain why this feature fails to be of prog-
nostic value in Stages II and III. Oestrogens
have been shown to stimulate phagocytic
activity in mice, and this may account for the
increased incidence in female patients.
)TERS
with DMBA (1-200 ng/ml) or TPA (1-1000
ng/ml) and fixed in situ for chromosome
analysis at later stages. Within one day of
treatment with a single dose ofDMBA, mouse
epidermal-cell chromosomes show altered
configurations such as metacentric chromo-
somes and chromatid fragments. Five days
after treatment triradial and quadriradial
formations are seen. At similar concentra-
tionsofDMBA, humanepidermal-cellchromo-
somes show no such aberrations, but there
appears to be an increase in the level of
aneuploidy above that in control culturqs.
Addition ofa single dose ofTPA to any ofthe
epidermal-cell cultures has no effect on chro-
mosome configuration, aneuploidy or poly-
ploidy. Autoradiographic studies are being
conducted to provide data concerning the
growth characteristics of the cultures at
different stages following treatment.
VOLUMETRIC INCREASES IN BLOOD
VESSELS DURING EPIDERMAL
CARCINOGENESIS. B. AL-AzZAWI &
F. H. WHITE, Department of Human Biology
and Anatomy, University ofSheffield.
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The aim of the present investigation is to
quantify changes in blood-vessel volume in
skin after the topical application of 7,12
dimethyl-benz(cx)anthracene (DMBA). The
dorsal skin of 20 male Syrian hamsters was
shaved and they were assigned to 4 groups of
5 animals. The first group received no DMBA
applications and served as a control, whilst
the others were treated 3 x /week with a 0-5%
solution of the chemical carcinogen DMBA.
Five animals were sacrificed after 9, 12 and
16 weeks of application. Tissue samples were
obtained and routinely processed for light
microscopy. Representative samples were
analysed using a MOP AMO3 (Kontron) semi-
automatic image analyser. The areas ofblood
vessels in both dermis and hypodermis were
estimated for the normal and for each experi-
mental group, as were the areas ofdermis and
hypodermis. From this data volume densities
could be calculated. The blood-vessel volume
densities for both dermis and hypodermis of
the normal control group were 0-0009 and
0-0040 respectively. The results show pro-
gressive increases in volume densities in both
dermis and hypodermis after both 9 and 12
weeks application ofDMBA, and there was a
pronounced increase in vascularity in animals
after 16 weeks treatment. Our results support
the concept that DMBA application increases
the volume of blood vessels in the adjacent
connective tissue. However, as yet we do not
know whether this is due to an increased
production (angiogenesis) or is simply a
reflection ofthe inflammatory response which
invariably accompanies carcinogenesis.
STEREOLOGICAL INVESTIGATIONS
OF DESMOSOME FREQUENCY DUR-
ING ORAL CARCINOGENESIS. F. H.
WHITE & K. GoHARi, Department of Oral
Pathology, University ofSheffield
Desmosomes are membrane specializations
which are responsible for intercellular attach-
ment. There are many subjective reports
describing alterations in desmosomes in
malignant lesions. The development ofstereo-
logical methods (Weibel, 1969, Int. Rev. Cytol.,
26, 235) now enables morphology to be placed
on a quantitative basis. Thus the aim of this
investigation was to quantify desmosome
frequency using stereological methods during
sequential DMBA carcinogenesis in hamster
cheek pouch. After DMBA treatment, pouch
samples were removed and epithelial lesions
were classified into hyperplasia, dysplasia and
carcinoma groups. Untreated pouch epithe-
lium served as a control group. Representa-
tive samples from 5 animals in each group
were used to obtain electron micrographs of
definedbasal, spinousandgranularcells.Using
a test lattice comprising parallel lines, inter-
sections of the lattice lines with desmosomes
and plasma membrane were counted. Using
these data the number of desmosomes per
unit area of plasma membrane (Ns) was esti-
mated from the formula Ns=NIAI-A where
N is the number ofdesmosomes, A the surface
area on which they are present and a the
mean desmosome diameter. Ns values were
obtained for basal, spinous and granular
layers ofeach group. The results indicate that
during chemical carcinogenesis the parameter
Ns decreases by more than 50% in basal and
spinous cells. This decrease in desmosomal
frequency may be a requirement for car-
cinoma cell invasion and metastasis.
ALTERATIONS IN THE FREQUENCY
OF GOLGI COMPLEXES DURING
ORAL CARCINOGENESIS IN THE
HAMSTER CHEEK POUCH. F. H. WHITE
& K. GOHARI, Departments of Oral Pathology
and Human Biology and Anatomy, University
ofSheffield
The metabolic characteristics of tumours are
altered from their tissue of origin and it is
possible thatsuch alterations areaccompanied
by changes in the morphology ofintercellular
organelles. The present study evaluates the
possibility that the Golgi complex, which is
actively involved in the synthesis of cell-
surface carbohydrates, is altered in frequency
during the process ofchemical carcinogenesis.
This work is part of a larger morphometric
investigation to determine whether any
specific ultrastructural morphological altera-
tions exist which might be of value in the
detection of oral precancer. After application
of 0.5% DMBA to cheek pouches of Syrian
hamsters, tissue samples were obtained, pro-
cessed for electron microscopy and on the
basis of light-microscopical evaluation of
Araldite-embedded material were assigned to
hyperplasia, dysplasia and carcinoma stages
by strict criteria. Untreated epithelium served
as a control. Following a stratified sampling
procedure, micrographs from defined basal,
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spinous and granular layers were obtained
from normal and pathological stages, and
using point counting methods, the number of
Golgi complexes per unit volume of cyto-
plasm (NVGOL) was determined for each
cellular lyaer at each stage. Values for
NVGOL were similar in basal cells in normal
and all pathological stages. However in
spinous and granular layers, NVGOL decreased
progressively between normal and carcinoma
stages. These results may reflect the failure of
normal differentiation in carcinogen-treated
epithelium, and further morphometric infor-
mation on a variety of non-malignant epi-
thelial conditions is required before the value
of this parameter as a diagnostic indicator
can be determined.
QUANTITATIVE ALTERATIONS IN
NUCLEAR PORES DURING EXPERI-
MENTAL ORAL CARCINOGENESIS.
R. M. CODD, F. H. WHITE & K. GOHARI,
Departments of Human Biology and Anatomy
and Oral Pathology, University of Sheffield
Nuclear pores aresmall channels inthenuclear
envelope which permit the passage of large
molecules between the nucleoplasm and the
cytoplasm. We have previously described
methods for quantifying these structures in
normal hamster cheek-pouch epithelium, and
the present study was designed to establish
whether there are any quantitative changes
in the relative surface areas of nuclear pores
in premalignant epithelial tissues. Following
application of DMBA to hamster cheek-
pouches, tissue was removed, processed for
electron microscopy and semithin sections
examined in order to assign lesions to hyper-
plasia and dysplasia stages. Following a strict
sampling procedure, micrographs were ob-
tained from basal, spinous and granular-layer
nuclei for each pathological stage. Stereologi-
cal intersection counting was performed to
estimate the relative surface area of nuclear
pores present on the nuclear membrane
(SSnp,nm) for each cell layer at each patho-
logical stage. Initial results suggest that the
SSnp,nm is lower in both DMBA-treated
groups when compared to the untreated con-
trols. The observed decrease may reflect
alterations in cellular differentiation during
pre-cancer, such as decreased frequency of
tonofibrils and keratohyaline granules. We
are currently using similar methods to quan-
tify relative surface areas in carcinomas, and
are expanding the study to include para-
meters such as number of pores per unit
surface and mean pore diameter, in order to
characterize these morphological changes
more precisely.
LOSS OF BODY WEIGHT MODIFIES
COLONIC CARCINOGENESIS AFTER
SUBTOTAL JEJUNO-ILEAL BYPASS
IN RATS. J. B. BRISTOL & R. C. N. WIL-
LIAMSON, University Department of Surgery,
Bristol Royal Infirmary
Although small-bowel resection promotes
experimental intestinal carcinogenesis, sub-
total bypass may have a protective effect
(Williamson et al., 1980, Cancer Res., 40, 538).
Since changes in body weight might explain
the discrepancy, colorectal carcinogenesis was
studied after different types ofenteric bypass.
Male Sprague-Dawley rats weighing 117 +
0-8 g (s.e.) were given 6 s.c. weekly injections
of azoxymethane (15 mg/kg). One week later
each rat was subjected to 85-90o% jejuno-
ileal bypass (3 groups) or sham bypass
(SB), comprisingjejunaltransection,ileotomy,
and resuture. Bypass was (1) end-to-side;
(2) end-to-end with a Thiry-Vella fistula
(TVF) or (3) end-to-end with drainage of the
bypassed loop into the descending colon
(LDC). Twelve weeks after the initial opera-
tion, the self-emptying blind loop was re-
sected in halfthe rats with end-to-side bypass.
At 30 weeks the 61 surviving rats were killed.
SB rats weighed 586 + 23 g and had 3-9 + 1-0
colorectal tumours perrat. End-to-sidebypass
more than doubled the number of colorectal
tumours to 10-3 + 1-4 (P<0-01), despite
reducing body weight to 7300 that of SB rats
(P<0-001). Bypass with TVF or LDC caused
even greater weight loss (55% of SB). Colo-
rectal tumour yields of 5.3 +0-8 (TVF), and
5-8 + 1V2 (LDC) were not significantly different
from SB rats. In rats with end-to-side bypass,
resection of the blind loop did not alter the
final body weight; the number of tumours
(7 0 +2.7) was again greater than in SB rats
(P<0.05).
Jejuno-ileal bypass enhances colorectal
neoplasia. This effect is abolished by profound
reduction of body weight, but not by mid-
term resection ofthe bypassed loop.
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LABORATORY USAGE OF SOME SUS-
PECT CARCINOGENS. F. DEWHURST,
School ofLife Sciences, Leicester Polytechnic
Recent studies by Olin et al. (1980, Env. Res.,
22, 154) on Swedish chemists and by Searle
et al. on British chemists have produced some
evidence of a greater than expected incidence
oftumours. There is little ornoinformation on
exposure ofchemists tosuspected carcinogens.
A questionnaire safety survey of British
laboratories was carried out through "Labora-
toryNews" in 1973. Atotal of1178 replies was
received covering all types of laboratory.
Questions were asked concerning the usage of
certain types of suspect chemical carcinogen.
Less than 10% of replies stated sulphur
mustards were used, 1-5% of replies stated
nitrogen mustards, ethylene imines, beta
propriolactone thioacetamide and nitro-
samines were used, whilst 5-10% stated that
asbestos (finely powdered), beryllium, and
urethane were used. Between 10 and 20% of
replies reported epoxides, thiourea, diazo-
methane, acetamide,hydrazine,nickelpowder,
cadmium and arsenic and their compounds.
Chromium and its compounds were used by
34% of those replying, whilst the use of lead
and its compounds was reported by 4000.
The most commonly reported carcinogens
were the solvents chloroform (74% ofreplies),
carbon tetrachloride (66%) and benzene
(48%). Weekly or more frequent usage of
benzene was reported in 10% of replies, of
carbon tetrachloride in 17% and of chloro-
form in 24%.
Evidence in the survey showed serious
contamination of the laboratory atmosphere
with solvent vapour in about a third of all
cases. Inabout 15%, formaldehyde levels high
enough to cause eye irritation were noted.
CHLORAMBUCIL-INDUCED CHAN-
GES IN CHROMATIN METHYLA-
TION. M. L. RAMIREZ, R. SHEPHERD, S.
PINSKY, K. MCGHEE & K. R. HARRAP,
Department of Biochemical Pharmacology,
Institute of Cancer Research, Sutton, Surrey
Post-synthetic methylation of nucleic acids
and nuclear proteins is a putative regulatory
event in the function and structure of chro-
matin. Changes in methylation may also be
determinants of alkylating-agent toxicity,
in the same way as has been shown for
chromatin protein phosphorylation (Cancer
Res., 1979, 39, 4256). We studied the effects
of chlorambucil treatment on DNA and
nuclear protein methylation in sensitive (S)
and resistant (R) Walker 256 carcinosarcoma
cells in vitro (2h treatment) and in vivo (24h
treatment). Incorporation of [3H-methyl]-
methionine (Met) into whole cells or [3H-
methyl] S-adenosylmethionine (SAM) into
isolated nuclei was measured. At an ID50
dose, DNA, histone and non-histone methyla-
tion was stimulated in S cells but not in R
cells (Met assay). An IDso dose inhibited
methylation in both S and R cells. Similar
results were obtained using isolated nuclei,
where only histone methylation was detected
(non-histone methyl-transferases are cyto-
plasmic enzymes). DNA methylation at the
5 position of cytosine was inhibited at ID9o
doses. The transcriptional inducer, sodium
butyrate, at an ID9o dose in vitro (5 mmol/l
for 48 h) inhibited methylation by 50-70%,
whilst an ID10dose (2mmol/l, 24h) caused less
inhibition. Pretreatment with butyrate in-
hibited chlorambucil-mediated enhancement
of methylation. These data indicate that
changes in methylation of chromatin proteins
and DNAparalleled alkylating-agent toxicity.
Nuclear protein methylation has been asso-
ciated with chromatin condensation, and its
inhibition at lDgo doses correlated with the
loss ofheterochromatin observed inthese cells.
PHARMACOKINETIC INVESTIGA-
TIONS OF 5-FLUOROURACIL IN
BREAST CANCER PATIENTS. B. J.
McDERMOTT, H. VAN DEN BERG* & R. F.
MURPHY, Departments of Biochemistry and
*Therapeutics and Pharmacology, Queen's
University, Belfast
Studies on the urinary excretion kinetics of
5-fluorouracil (FU) were performed using an
ion-specific electrode (ISE) technique. FU
and metabolites contain organically bound
fluorine, which is degraded by oxygen-flask
combustion to fluoride ion for detection by
the electrode. Prior to estimation, FU and
metabolic products may be separated by gel
filtration on Bio-Gel P-2. Five patients
receiving i.v. bolus injections of FU (300-
500 mg) on each day of a 5-day combination
chemotherapeutic regime, were investigated.
Analysis of 24h specimens showed decreasing
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excretion of total organic fluorine with suc-
cessive doses, indicating accumulation of the
drug. Two patients, however, eliminated the
greatest amounts of FU and metabolites into
the urine on Day 3 oftherapy, when the drug
was administered alone. Sampling of 3
patients at timed intervals on Day 3 allowed
determination of their elimination kinetics
for FU (tl=37-4, 43-9 and 18-8 h). These
values are inconsistent with results from our
previous studies of plasma pharmacokinetics.
Using a gas-liquid chromatographic-electron
capture (GLC-EC) method, 2 phases of
elimination were described with tca= 12-1 +
1-0 (s.e.) min and tifi=123-5+22-2 min.
Assessment of the terminal portion of the
decay function has important therapeutic
considerations as it probably reflects clear-
ance of the active form of the drug from
tissues. Due to limitations in sensitivity of
the GLC-EC technique (20 ng/ml), interpreta-
tion of plasma profiles is difficult, and it is
suggested that the kinetic parameters esti-
mated from urinary-excretion data are more
accurate. Using a combination of the ISE
and GLC-EC methods, the excretion patterns
ofthe parent drug and individual metabolites
may be determined. The characterization of
metabolites separated by gel filtration has
yet to be completed.
FOLATE CATABOLISM: ALTERA-
TIONS IN MALIGNANT DISEASE.
A. M. SALEH, A. E. PHEASANT, J. A. BLAIR,
R. N. ALLAN & J. WALTERS, Department of
Chemistry, University ofAston in Birmingham
In rat, guinea-pig and man, folates are
catabolized to p-acetamidobenzoyl L-gluta-
mate (p-AcBG), p-acetamidobenzoate (p-
AcBA) and various pteridine fragments
(Choolun et al., 1980, Biochem. Soc. Trans.,
8, 568; Saleh et al., 1980, Biochem. Soc.
Trans., 8, 566). Folate catabolism is de-
creased in tumour-bearing rats (Barford &
Blair, 1978, Br. J. Cancer, 38, 122). In this
study, consenting hospital in-patients re-
ceived an oral dose of [2-14C] +[3',5',7,9-3H]
folic acid (5 mg folic acid) and urine was
collected for24h. Tenpatients with malignant
disease were compared with a control group
(5) suffering from other disorders. Cancer
patients excreted significantly (P<0-001)
less radioactivity in urine; 14-7 3H,
12.4% 14C of the dose compared to 32.0%
3H, 26.2% 14C for the controls. Where deter-
mined, faecal radioactivity was similar in the
2 groups (0.2-10.8% 3H, 0.3-28% 14C).
Total urinary scission-product excretion (p-
AcBG+pAcBA) was decreased in cancer
patients; 2.0% ofthe dose compared to 4.30o
by the controls. p-AcBG is derived from tissue
folate polyglutamates. Based on the radio-
activity retained in the tissues, the difference
in catabolism by the 2 groups is even more
marked: 1-0% of the retained 3H being ex-
creted as p-AcBG by the cancerpatients com:
pared to 2.4% by the controls. The mecha-
nism of folate breakdown may involve the
oxidation of labile reduced folate. Thus the
decrease in catabolism associated with malig-
nancy may be explained by the altered redox
state and anoxia oftumour cells.
INCREASED THERAPEUTIC ACTI-
VITY OF THIOTEPA IN EXPERI-
MENTAL MOUSE COLON TUMOURS
FOLLOWING NANDROLONE DECA-
NOATE PRE-TREATMENT. J. A.
DOUBLE, M. C. BIBBY & M. A. MUGHAL,
Clinical Oncology Unit, School of Medical
Sciences, University ofBradford
We have previously reported (Double &
Bibby, 1981, Br. J. Cancer, 42, 171; Bibby
et al., Br. J. Pharmacol., in press) that pre-
treatment with nandrolone decanoate (N.D.)
raises the LD50 of CCNU and 5FU in NMRI
mice without altering the anti-tumour acti-
vity against transplantable mouse colon
tumours. The present study reports an
extension of this work, using 2 tumour
lines with differing histology and growth
characteristics, both of which are sensitive
to Thiotepa. MAC 26 is a slow-growing well
differentiated adenocarcinoma, whereas MAC
13 is less well differentiated and grows more
rapidly. The differing growth rates of these
tumour lines necessitated the use of 2
different treatment protocols. The growth of
MAC 26 can be easily followed by serial
caliper measurements. Chemotherapy begins
14 days after transplantation, when
tumours have a mean volume of - 250 mm3.
The rapid growth of MAC 13 makes this
method impractical. Chemotherapy in this
line is administered 2 days after implantation,
and the effects are determined 14 days later
by comparison of tumour weights. Peripheral
WBC counts in normal mice and mice receiv-
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ing ND and thiotepa were measured with a
Coulter S plus. In both systems ND had no
significant effect on tumour growth or on the
anti-tumour action of thiotepa, but reduced
toxicity, leading to an increase in therapeutic
index. Although this reduction in toxicity
was less than we have previously reported for
CCNU and 5FU, the dose-response curve for
thiotepa is much steeper than for these other
agents. Peripheral WBC counts indicate that
there is a significant protection of the haemo-
poietic system, which in a corresponding
clinical situation would be of importance to
patients undergoing cytotoxic therapy with
thiotepa.
FACTORS INFLUENCING KILLING
OF HUMAN TUMOUR CELLS BY
MELPHALAN IN VITRO. V. D. COUR-
TENAY & JUDITH MILLS, Radiotherapy Re-
search Unit, Institute of Cancer Research,
Sutton, Surrey
In vitro sensitivity testing of chemothera-
peutic drugs against tumour cells from biopsy
specimens is being widely investigated as a
possible means ofpredicting the clinical sensi-
tivity of tumours in individual patients. It is
therefore important to determine in vitro test
conditions such that cell survival at a given
drug dose may be directly related to in vivo
response.
In these studies using cell suspensions pre-
pared from a human pancreatic adenocar-
cinoma xenograft (HX32) and treated in
vitro with melphalan, survival was assayed by
an agar colony technique. The effect of cell
disaggregation technique, cell sedimentation,
cell concentration, serum concentration and
pH during treatment was examined. A dose
modification factor greater than 3 was
obtained, depending on the conditions of
treatment and recovery. Tumour cell survival
was found to depend on serum concentration
during treatment and on the type of serum
used both during and after exposure to drug.
Incubating disaggregated cells at 37°C for 1 h
before treatment also affected survival. The
shape of survival curves was dependent on
whether cells were allowed to settle out during
treatment or maintained in suspension.
These studies indicate some possible sources
of error in using "in vitro" tests to rank "in
vivo" effectiveness of drugs with different
pharmacological properties and modes of
action-
THE EFFECTS OF CYCLOPHOSPHA-
MIDE AND ITS DERIVATIVES ON
ADENYLATE CYCLASE ACTIVITY
AND PROTEIN SYNTHESIS. L. A.
FITTON, G. J. HUNTER & B. E. P. SWOBODA,
Department of Chemistry and Molecular
Sciences, University of Warwick, Coventry
Nitrogen mustard chemotherapeutic agents
are considered to obtain their effect by cross-
linking DNA, though other cellular targets
have been implicated (Eur. J. Cancer, 1977,
13, 1363). We have examined the effects of
cyclophosphamide (CP) and its metabolites
on the enzymes of cyclic-nucleotide metabo-
lism and protein synthesis.
CP, 4-keto-CP (KP) and phosphoramide
mustard (PM) (< 15 mmol/l) were found to
have no effect on basal or stimulated hepatic
adenylate cyclase activity. 4-hydroperoxy-CP
(HP, 5 mmol/l), was found to inhibit enzyme
activity (50%o) and completely abolished the
effect ofglucagon but only partially abolished
the stimulatory effect of fluoride. Whereas
CP and KP are "inactive", PM is a potent
alkylating agent and is considered as the
"ultimate" alkylating metabolite of CP.
These results may be explained by the unique
reactivity of HP (Cancer Treat. Rep., 1976,
60, 355). Similar specificity has been observed
in the sensitivity of cAMP phosphodiesterase
and protein kinase for HP (Biochem. Pharma-
col., 1977, 26, 1469).
In a separate series of experiments, we
have found that protein synthesis is inhibited
by low concentrations of CP metabolites.
HP (10 mmoljl), inhibited protein synthesis in
rabbit reticulocyte lysate by 50%0. PM and
HN2 showed only a slight effect at this con-
centration (up to 10% inhibition).
DIFFERENTIAL RESPONSES TO X-
IRRADIATION, 5-FLUOROURACIL
OR METHOTREXATE IN A RANGE
OF HUMAN AND MURINE TUMOUR
CELLS IN VITRO. A. S. BELLAMY, R. D. H.
WHELAN & B. T. HILL, Laboratory of Cellular
Chemotherapy, ImperialCancerResearchFund,
London
Clinical studies have indicated that prior
radiation reduces response to subsequent
chemotherapy. Studies were undertaken to
determine whether there is any correlation
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between in vitro sensitivities to X-irradiation
and response to methotrexate (MTX) or
5-fluorouracil (FU) in a range of mammalian
cell lines. Sensitivity was assessed by colony-
forming assays, in soft agar or on plastic.
Drug-resistant lines were derived in vitro
from murine L5178Y lymphoma cells by con-
tinuous exposure to either MTX, FU or both.
A radiation-treated line was obtained by
exposure to 10 fractions of 2 Gy. The results
showed a range of sensitivities to radiation,
with Do values of32-58 rads, which appeared
inversely correlated with response to MTX.
No such relationship was seen in the case of
FU.
Four human tumour-cell lines showing a
range ofsensitivities toMTX were thenexam-
ined. SCC-T/G and Hep2 were derived from
primary squamous-cell carcinomas of the
tongue and larynx respectively, and LAN-1
and CHP-100 derived from neuroblastomas.
These human lines also showed a range of Do
values for radiation of0-6-1-8 rads. No corre-
lations involving FU were noted, as for the
murine cells. In addition, no relationship was
seen betweentheresponsestoMTX and FU in
any of the cell lines tested. Furthermore, no
clearrelationship between sensitivity to MTX
and resistance to radiation was shown. This
aspect is being investigated further, using
specific drug-resistant and radiation-resistant
human tumour-cell lines.
A CYTOFLUORIMETRIC STUDY OF
THE COLLATERAL SENSITIVITY
OF A METHOTREXATE-RESISTANT
CELL AGAINST THE VINCA ALKA-
LOIDS. A. McGowN, D. G. POPPITT &
B. W. Fox, Paterson Laboratories, Christie
Hospital and Holt Radium Institute, Man-
chester
L1210 cells sensitive and resistant to MTX
exhibit a collateral sensitivity towards the
Vinca alkaloids. The cell cycle perturbations
inducedbytheVinca alkaloids were examined
by flow cytometry and it was shown that both
the sensitive and resistant cell lines became
blocked in G2, but that the resistant line re-
mained blocked at much lower levels of vinca
alkaloid than the sensitive. It is concluded
that drug resistance due to gene reduplication
may be accompanied by an increased diffi-
culty in undertaking mitosis, and that the
Vinca alkaloids may exaggerate this effect.
CARBOHYDRATE-LINKED MELA-
MINE DERIVATIVES. S. P. LANGDON,
R. J. SIMMONDS & M. F. G. STEVENS, C.R.C.
Experimental Chemotherapy Group, Depart-
ment of Pharmacy, University of Aston in
Birmingham, and G. Atassi, Institut Jules
Bordet, 1000 Brussels
Efforts to improve the water solubility of
hexamethylmelamine (HMM, 1) by molecular
modification generally produce dyschemo-
therapeutic effects (Cumber & Ross, 1977,
Chem. Biol. Interactions, 17, 349). We have
developed a synthetic method to conjoin
sugars and cytotoxic melamine fragments:
for example interaction of the quaternary
salt (2) with glucosamine or D-glucose yields
the "sweet melamines" (3) and (4) respec-
tively.
R
N/>N
Me2Nl vNMe2
(1) R = NMe2
(2) R = NMe3Cl
CH2i 0'
0
HO N=\NMe2
HNNNMe
(3)
CH2OH N==NMe2
00 ' /N
OHa N y NMe2
HO
OH
(4)
Despite their improved solubilities these
new agents have no inhibitory effects on the
mouse M-5076 ovarian carcinoma, whereas
HMM and related cogeners are active (Table).
Compound TVI (O°)*
RR= NMe2 70
(1) R= NHMe 65
R =N(Me)CH2OH 67
(3) inactive
(4) inactive
Optimal
doset
(mg/kg)
150
150
160
200t
300t
* Tumour volume inhibition on Day 24.
t Drugs injected on alternate days over 21-day
period.
$ Maximum dose tested.
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SERUM 5a-ANDROSTANE-3ot, 17,B-
DIOL IN PATIENTS WITH PROSTA-
TIC TUMOURS. R. GHANADIAN, C. M.
PUAH & G. WILLIAMS, Prostate Research
Laboratory, RoyalPostgraduate MedicalSchool,
Ducane Road, London, and Institute of
Urology, University of London
Concentrations of serum 5a-androstane-3&,
17/3-diol (diol) were estimated in patients
with benign and malignant tumours of the
prostate. This androgen which is a metabolite
of 5oe-dihydrotestosterone (DHT) has been
implicated in the growth and functional acti-
vities oftheprostate. Thirty-two patients with
provenprostatic cancer (Ca) aged51-85 years,
32 patients withbenign prostatic hypertrophy
(BPH) aged 54-84 years and 24 normal sub-
jects aged 51-80 years were investigated.
The mean + s.e. for serum concentrations of
diol for BPH, Ca and normal subjects were
813 +43, 524 + 35 and 685 + 28 pM respec-
tively. Statistical analyses of the results
showed that the level of this steroid in BPH
patients was significantly higher than either
the normal subjects (P<0.05) or Ca patients
(P<0-001). Furthermore, the level of this
androgen in Ca patients was significantly
lower than that of the normal group (P<
0.005). The higher level of diol in BPH
patients than in the aged-matched control
group corresponds to that reported for 5Scx-
dihydrotestosterone, which is an immediate
precursor of this stero id (Ghanadian et al.
1977, Br. J. Urol., 49, 541). Although a
significant difference has been found between
the levels of this androgen in patients with
GPH and Ca, the scattered values within each
group does not provide an index to differen-
tiate the 2 types oftumours.
CORRELATIVE STUDIES BETWEEN
ENDOGENOUS STEROIDS AND
STROMAL-EPITHELIAL COMPOSI-
TION IN HUMAN BENIGN HYPER-
TROPHIED PROSTATE. C. M. PUAH
& R. GHANADIAN, Prostate Research Labora-
tory, Royal Postgraduate Medical School,
Ducane Road, W.12 OHS, and Institute of
Urology, London WC2.
The relationship between endogenous steroids
and the compositions ofstromal and epithelial
cells in prostatic tissues were investigated in
order to evaluate differential localization of
steroids within cell types. Tissues were ob-
tained from 14 patients aged 54-79 years
with benign prostatic hypertrophy (BPH).
Prostatic tissues were removed by retropubic
prostatectomy. The clinical diagnosis of the
disease was confirmed by histological exam-
ination of the operative specimen. Testo-
sterone (T), 5a-dihydrotestosterone (DHT),
5ac-androstane-3ca, 17,B-diol (diol) and oestra-
diol-17f, (E2) were measured by radioimmu-
noassay developed in our laboratory. Rep-
resentative sections of each tissue were
stained with H & E. Morphometric analyses
were carried out by point counting with an
aid of a superimposed ocular grid (100 Sq.).
The results showed that E2 is predominantly
localized in the stroma (r=0.63, P<0.005),
whereas diol is mainly associated with the
glandular fraction, epithelial+acinar (r=
0.53, P<0.05). Further associations were also
found between the ratios diol/E2 with both
epithelial (r=0 57, P<0 05) and glandular
fractions (r=0-70, P<0.01). Neither T nor
DHT revealed any preferential localization
with epithelial or stromal elements. It would
appear from this study that an androgen-
oestrogen balance may be involved in the
changes of stromal-epithelial composition
and hence in the secondary growth of the
prostate.
RECTAL BIOPSY IN THE STAGING
OF NON-HODGKIN'S LYMPHOMAS.
R. C. F. LEONARD & C. MCCORMICK, Oxford
Lymphoma Group, Churchill Hospital, Oxford
In a study of non-Hodgkin's lymphoma,
patients were routinely subjected to rectal
biopsy as a part of the staging procedure at
presentation. In every case the mucosa was
macroscopically normal, but histological
examination revealed evidence of lymphoma
deposits in 16/80 patients biopsied. Thesiteof
disease was lamina propria, often with exten-
sion through the muscularis mucosa. Analysis
of patients by (Kiel) histopathology group,
site of clinical disease and stage showed that
microscopic invasion of the bowel mucosa
occurred in most sub-groups except localized
high-grade lymphomas. Thus in clinical Stage
III or IV low-grade lymphomas the rate of
detection was much higher, particularly in
the centroblastic-centrocytic lymphomas and
lymphoplasmacytoid lymphomas. These find-
ings give further support to the concept of
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disease being widespread at presentation
among low-grade non-Hodgkin's lymphomas.
THE PRESENCE OF RETINOIC ACID
RECEPTOR IN HUMAN BLADDER
TUMOURS. S. L. FAGG, A. HUGHES, P.
DAWSON-EDWARDS & M. A. HUGHES, Depart-
ment of Surgical Immunology, Department of
Medicine and Department of Urology, Queen
Elizabeth Hospital, Birmingham
Specific intracellular receptors for retinoic
acid (RAR), analogous to receptors for
steroid hormones, are found in a variety of
malignant tissues including human lung,
breast, cervical, endometrial and ovarian
tumours (Ong et al., 1975, Science, 190, 60;
Kung et al., 1980, Cancer Res., 40, 4265.
Palan et al., 1980, Cancer Rcs., 40, 4221).
There is no previous report ofRAR in bladder
tumours. In this study RAR was measured in
human bladder tumour specimens obtained
by transurethral resection. Tumour specimens
were frozen in liquid N2, and pulverized with
a Mikro-Dismembrator. The powder was
suspended in 4 vols (w/v) ofIcold buffer(10mM
Tris, 15mM EDTA, 10mM DTT, 1M4m
glycerol, pH7 4) andcytosolpreparedbyhigh-
speed centrifugation (240,000 g x 1 1 h).
Specificbinding wasassessedusing anagarose-
gel electrophoresis system (Huber et al., 1978,
J. Natl Cancer Inst., 61, 1375), following incu-
bation with labelled RA (40 Ci/mmol-a gift
from Roche, Nutley, N.J.) together with the
appropriate controls containing an excess of
unlabelled RA. Retinol did not compete in
this system nor was there any specific binding
of RA in serum. RAR was detectable in the
cytosols of 6 specimens (ranging from 0-15-
1-13 pmol RA/mg cytosol protein). There
was no detectable RAR in 3 specimens. These
results suggest that RA and its synthetic
analogues may be useful in the treatment of
some bladder tumours. This study is con-
tinuing, and will be combined with a clinical
trial using retinoids in the treatment of
patients with bladder tumours.
REDUCED GVHR in F1 HYBRID MICE,
INJECTED WITH PARENTAL LYM-
PHOID CELLS, IN THE PRESENCE
OF AN F1 TUMOUR. T. WHITMARSH-
EVERISS & M. 0. SYMES, Department of
Surgery, University of Bristol
A graft vs host reaction (GVHR) was
induced in (A x CBA(T6)) F1 mice by injec-
tion of A-strain spleen cells. The magnitude
of the resulting GVHR was measured by an
increase in spleen weight. The presence of an
F1 tumour less the GVHR in 5 experiments.
At the same time tumour size was reduced in
animals undergoing GVHR than in animals
receiving tumour alone. These effects were
not seen in F1 hybrid animals bearing an
A-strain tumour. Excision of an F1 tumour
from F1 hosts, which then received A-strain
spleen cells, led to a greater GVHR thanl in
animals from which the tumour was not
excised. Thus the reaction of A spleen cells
against an F1 tumour may protect an F1
host from GVHR by preoccupation of the A
cells.
Spleen cells from F1 mice were transferred
to 3-8-day F1 litter mates, atvariousintervals
after induction of GVHR by injection of A-
strain spleen cells. Other F1 mice from the
same litters received cells from F1 mice under-
going GVHR in the presence ofan F1 tumour.
A spleen cells from the tumour-bearing F1
hybrids induced less GVHR in F1 litter mates,
than parental cells from non-tumour-bearing
hybrids. Thus the presence of a tumour also
depressed injected parental cell reactivity.
APPLICATION OF A MONOCLONAL
ANTIBODY TO RAT HEPATOCYTES
IN THE STUDY OF RAT LIVER
CARCINOGENESIS. C. HOLMES, B. GUNN,
E. B. AUSTIN and M. J. EMBLETON, Cancer
Research Campaign Laboratories, University
of Nottingham
BALB/c mice were immunized with rat
hepatocytes, isolated from regenerating rat
liver by perfusion and disaggregation with
collagenase. Spleen cells from an immunized
mouse werefusedwithP3NS1 mousemyeloma
cells to produce hybridomas secreting anti-
bodies to rat hepatocytes. After screening
against cells derived from different rat
tissues, one hybridoma was selected which
produced antibody reacting preferentially
with cells from regenerating and normal
syngeneic liver, allogeneic liver and foetal
liver. This antibody showed a borderline
reactivity with normal rat kidney, but was
completely negative for a range of other rat
tissues and guinea-pig hepatocytes. The
hybridoma was cloned, and is now producing
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a monoclonal antibody with identical speci-
ficity.
Preliminary tests have been carried out to
determine whether the expression ofthe anti-
gendetected bythis antibodyis altered during
liver carcinogenesis, and the results indicate
that it is reduced or absent in some rat
hepatomas. These studies are being extended
to establish the stage of carcinogenesis at
which this change in antigen expression
occurs.
A DIFFERENCE IN THE GROWTH
RESPONSE OF CAPILLARY AND
AORTIC ENDOTHELIAL CELLS TO
TUMOUR ANGIOGENESIS FACTOR
(TAF). A. L. BRIERLEY, Christie Hospital,
Manchester
Capillary-derived, and aorta-derived endo-
thelial cells were grown on plastic dishes and
native collagen gels. Addition ofTAF to these
cultures and examination of subsequent cell
numbers revealed: (a) Capillary cells growing
on native collagen gels were stimulated to
proliferate by addition ofTAF; (b) No stimu-
lation was observed for either aorta-derived
cells growing on plastic or native collagen
gels, or for capillary cells on a plastic sub-
strate.
This data suggests a functional difference
between large and small-vessel endothelial
cells, a difference which has wide implications
when undertaking studies on diseases involv-
ing endothelial-cell disorders.
DETECTION OF HUMAN OSTEO-
GENIC-SARCOMA CELL-SURFACE
ANTIGENS USING RADIOLABELLED
ANTI-TUMOUR MONOCLONAL AN-
TIBODIES. F. A. DAWOOD, M. R. PRICE,
M. J. EMBLETON & R. W. BALDWIN, Cancer
Research Campaign Laboratories, University
ofNottingham
Monoclonal antibodies against an osteogenic-
sarcoma cell line (791T) were prepared by
production and cloning of a somatic-cell
hybrid between spleen cells from 791T-
immunized mice and the mouse myeloma
P3-NS1. Antibodies (JgG2 subclass) produced
by 2 clones (36/3 and 48/15) were selected
on the basis of their preferential reactivity
with osteogenic-sarcoma cells, in the 1251-
Protein A cell-binding assay (Embleton et al.,
1981, Br.J. Cancer, 43,582). Afterpurification
of antibodies by their affinity to Sepharose-
Protein A, the preparations wereradiolabelled
with 125J using chloramine T. The pattern of
rebinding oflabelled monoclonal antibodies to
tumour cell lines was similar to that demon-
strated using the 125I-Protein A cell-binding
test, though the sensitivity ofthe direct bind-
ing test was less than that of the indirect-
binding assay. Cold-antibody inhibition of
binding oflabelled antibodies established that
the 2 antibodies from hybridomas 36/3 and
48/15 detected 2 different surface antigens
on 791T cells. Serum samples of known anti-
body reactivity from the 791T sarcoma donor
failed to inhibit the binding of radiolabelled
monoclonal antibody, suggesting that autoch-
thonous host reactivity was directed against
different antigenic targets.
A COMPARISON OF THE CYTO-
TOXIC EFFECTS OF ADRIAMYCIN
AND mAMSA ON MAMMALIAN
CELLS IN VITRO. C. WEST, E. SMITH,
N. BARRASS, I. STRATFORD & G. ADAMS,
Physics Department, Institute of Cancer Re-
search, Sutton, Surrey
Adriamycin (ADM) and the anilinoacridine
mAMSA are thought to be cytotoxic because
of their ability to interchelate between adja-
cent base pairs in DNA. Whereas ADM has
been in use for many years, mAMSA is only
in the initial stages ofclinical testing, and has
been considered by some as an alternative to
ADM.
In this work we have compared the actions
of ADM and mAMSA in Chinese hamster
V79 cells in vitro, using cell survival and
sister-chromatid exchange as end-points.
Equimolar concentrations of ADM and
mAMSA show similar toxicities towards
exponentially growing cells, and both drugs
are less effective in killing chronically hypoxic
and plateau-phase cells. Cytotoxicity to
thermotolerant cells (41°C for 16 h previously)
and cells held at a low pH, show little differ-
ence from that for exponential cells. Pre-
treating cells with misonidazole underhypoxic
conditions reduces the toxicity of both ADM
and mAMSA. In addition, an ADM resistant
cell line, V79-177 (Harris et al., 1979, Int.
J. Radiat. Oncol. Biol. Phys., 5, 1235) was
cross-resistant to mAMSA. Finally, low equi-
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molar doses of both drugs were found to
cause similar increases in the levels of SCE
inV79 cells.
THE CYTOTOXIC AND RADIO-
SENSITIZING EFFECTS OF Rh(II)
CARBOXYLATES. R. CHIBBER, I. STRAT-
FORD, B. LEE & G. ADAMS, Physics Depart-
ment, Institute of Cancer Research, Sutton,
Surrey, and School of Natural Sciences, Hat-
field Polytechnic, Hatfield, Herts
Three Rh(I1) carboxylates have been syn-
thesized and tested as cytotoxic and radio-
sensitizing agents in Chinese hamster V79
cells in vitro. These compounds were the
butyrate, propionate, and acetate. Survival
curves were generated for each compound as a
function of drug concentration, contact time
and temperature. These data showed that
toxicity was in the order butyrate>pro-
pionate >acetate. The magnitude of the dif-
ferences in toxicity is indicated by the con-
centration of each compound required to
give a surviving fraction of 041 in 2 h; viz.:
4-2 x 10-7, 4-5 x 10-6 and 4*4 x 10-5M for the
butyrate, propionateandacetaterespectively.
For comparison 10-5 cis-PtC12 (NH3)2 is
required to give the same level of toxicity.
All 3 compounds studied showed greater
toxicity to hypoxic cells. Of the 3 car-
boxylates, only the acetate showed any
ability to radiosensitize hypoxic cells. At non-
toxic concentrations, enhancement ratios up
to 1-5 were obtained.
These results suggest thatthe mechanism(s)
of toxicity and radiosensitization by the Rh-
(IT) carboxylates are different.
21
311